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            Abstract 
 Gain of function NOTCH1 mutations are common in both patients with T-ALL 
and in mouse models of the disease. Inhibiting the Notch pathway in T-ALL cell lines 
results in growth arrest and/or apoptosis in vitro, suggesting a requirement for Notch 
signaling in T-ALL. Therefore, we sought to examine the role of Notch1 signaling in 
both premalignancy and in the maintenance of leukemic growth. Using a murine model 
of T-ALL, in which expression of the Tal1 and Lmo2 oncogenes arrests thymocyte 
development, our preleukemic studies reveal that Notch1 mutations are early events that 
contribute to the clonal expansion of DN3 and DN4 progenitors. We also demonstrate 
that progenitors are maintained within the tumor and are enriched in leukemia-initiating 
cell (L-IC) activity, suggesting Notch1 may contribute to L-IC self-renewal. By studying 
the effects of Notch signaling in murine T-ALL cell lines, we also demonstrate that 
Notch1 promotes the proliferation and survival of leukemic blasts through regulation of 
Lef1 and the Akt/mTOR pathways.  
 Given that T-ALL cell lines are dependent on Notch signaling in vitro, we 
investigated the effects of Notch inhibition in vivo. We provide evidence that Notch1 can 
be successfully targeted in vivo and that Notch inhibition, with γ-secretase inhibitors 
(GSIs), significantly extends the survival of leukemic mice. We also demonstrate that 
administration of GSIs in combination with rapamycin inhibits human T-ALL growth 
and extends survival in a mouse xenograft model. Given that NOTCH1 may be required 
to maintain both L-IC and bulk leukemic growth, targeting NOTCH1 may prove to be an 
efficacious targeted therapy for T-ALL patients with aberrant NOTCH1 activation.
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 Acute lymphoblastic leukemia (ALL) is a malignancy that affects cells along the 
B or T-cell lineage. It is the most common form of leukemia in pediatric patients, as it 
accounts for 50% of all hematopoietic malignancies 1. T-cell acute lymphoblastic 
leukemia (T-ALL) is a subtype of ALL that accounts for 15% and 25% of all pediatric 
and adult ALL cases, respectively 2-4. Patients with T-ALL often exhibit high levels of 
circulating blasts in the peripheral blood, organ and central nervous system infiltration, 
and a thymic mass that can present as respiratory distress at diagnosis 5. 
 The development of T-ALL is a multi-step process involving a number of genetic 
events. Often, these events deregulate pathways that result in abnormal cellular 
proliferation, survival, differentiation and self-renewal. Chromosomal translocations 
contributing to T-ALL are rare, but often juxtapose genes to the T-cell receptor (TCR) 
locus, which is highly expressed in developing thymocytes. To date deregulation of genes 
including HOX11, HOX11L2, HOXA, TAL1, LYL1, LMO1, LMO2, NOTCH1 and c-MYB, 
PTEN, c-MYC, FBXW7, and WT1 have been documented to contribute to T-ALL 6-16. 
 Advancements in treatment regimens have increased survival rates dramatically 
for many types of leukemia, including B-cell acute lymphoblastic leukemia (B-ALL) 
17,18. However, patients with T-ALL, particularly those with TAL1 misexpression, have a 
poorer prognosis 5. Greater than 50% of patients with TAL1 misexpression will relapse 
despite intensive chemotherapy and many eventually die from the disease 5. For those 
patients who achieve remission following traditional chemotherapy, there can often be 
long-term side effects, including organ damage and/or failure, learning issues due to 
intrathecal prophylaxis, and the development of secondary malignancies such as acute 
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myelogenous leukemia (AML) 19. However, some patients, including those with 
NOTCH1 mutations, have a favorable prognosis 20,21. In these patients, perhaps targeted 
therapy instead of intensive broad based chemotherapy should be considered. Therefore, 
there is an urgent need for understanding the pathogenesis of T-ALL and ultimately, for 
the rational design of targeted therapies that can exploit the molecular abnormalities 
driving this malignancy.  
 
TAL1 is a basic helix-loop-helix protein required for normal hematopoiesis. 
          The T-cell acute lymphoblastic leukemia-1 gene (TAL1) (also known and SCL and 
TCL5) encodes a 42 kD class II basic helix loop helix (bHLH) protein 22 as well as a 
truncated 22kD form, which occurs as a result of translational initiation at an internal 
methionine 23,24. Tal1 is expressed in mouse embryonic tissues at embryonic day 7.5 and 
in adult erythroid, mast, megakaryocytic, and myeloid cells 25. Tal1 is also expressed in 
murine endothelial cells and in cells of the developing and adult brain 25-27. 
Hematopoietic stem cells (HSCs) and committed multipotent progenitors (CMPs) express 
Tal1, however Tal1 expression is silenced during early thymocyte development (double 
negative stage 2, DN2) and is not expressed in mature T-cells 28-30. 
 Tal1 expression is required for a number of normal developmental processes 
including the development of blood lineages 31,32. Tal1 -/- mice die at embryonic day 8.5-
10 due to a specific lack of blood and yolk sac hematopoiesis 31,33. Tal1 is also required 
for embryonic angiogenesis, erythroid and megakaryocytic differentiation and for HSC 
formation 31-36.  
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 As a class II bHLH protein, Tal1 does not homodimerize but instead forms 
heterodimers with class I bHLH E2A proteins such as E2-2, E47, E12, and Heb, which 
can bind DNA as heterodimers 37-39. During erythroid and megakaryocyte differentiation, 
Tal1 is part of multi-protein transcriptional complex containing E2A, Lmo2, Ldb1, 
Gata1/2 and Sp1 40-42. This multi-protein complex can bind E-box-Gata sites, and recruit 
co-activators (such as p300 43 and p/CAF 44) or co-repressors (such as mSin3A 45) to 
regulate transcription.  
 
TAL1 misexpression is observed in 60% of T-ALL patients. 
 The TAL1 gene was first identified in a patient with T-ALL in which a rare 
translocation, t(1;14)(q33;11), juxtaposed TAL1 on chromosome 1 to the TCRδ locus on 
chromosome 14 22, and resulted in TAL1 overexpression. A t(1;7)(p32;q35) translocation 
has also been described, which juxtaposed TAL1 to the TCRβ locus 46. In an additional 
20% of T-ALL patients, TAL1 is overexpressed via a 90-kilobase deletion that places 
TAL1 under control of the SCL-interrupting-locus (SIL) promoter, which is highly active 
in many tissues 47-50. Together these genetic events account for the TAL1 overexpression 
that is seen in 25% of all T-ALL cases. However, recent studies reveal TAL1 
overexpression accounts for as many as 60% of childhood and 45% of adult T-ALL cases 
50. This has led many to hypothesize that a currently unknown regulator of TAL1 may be 
commonly inactivated in T-ALL 50.   
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Mouse models of Tal1-mediated disease  
 Many strategies have been used to misexpress Tal1 in developing thymocytes 
including the CD2 and SIL promoters. However, these mice fail to develop leukemia 51-
54. In transgenic mice, ectopic expression of Tal1 using the proximal Lck promoter does 
result in a leukemic phenotype, with 27% of mice developing disease within 350 days 55. 
Further analysis of these mice reveal the development a lymphoblastic disease, with 
evidence of a thymic mass, and infiltration of the central nervous system, kidney, liver, 
and spleen 55. Collectively, these studies suggest that expression in a specific thymic 
progenitor and/or levels of Tal1 expression are critical for disease induction. 
 Lck-Tal1 preleukemic mice exhibit a thymocyte differentiation arrest at the 
double negative 3 (DN3) stage 56. During this developmental stage, E47 heterodimerizes 
with Heb and regulates the expression of genes critical to normal development such as; 
recombinase activating genes 1 and 2 (Rag1/2), pre T-cell antigen receptor alpha (Pre-
Tα), TCR α/δ, CD4, CD3, and CD5 (reviewed in 57). In human and mouse T-ALL cells 
TAL1/E47 and TAL1/HEB heterodimers are detected 38,56, suggesting Tal1 may interfere 
with E protein functions. To test this idea we mated our Lck-Tal1 transgenic mice to Heb 
or E2A heterozygous mice to generate Tal1/Heb+/- and Tal1/E2A+/- cohorts. Consistent 
with the idea that Tal1 interferes with E protein function, Tal1/Heb+/- and Tal1/E2A+/- 
mice have a more severe perturbation in thymocyte development and disease acceleration 
compared to mice that only express Tal1 58. Tal1/E2A+/- preleukemic thymocytes also 
exhibit significant reductions in the expression of E47/Heb regulated genes on a per cell 
basis compared to that observed in Ta11 preleukemic thymocytes 58. 
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 In T-ALL patients, TAL1 activation is often associated with secondary genetic 
events including p16/INK4A and p14/ARF loss, and c-MYC, LMO1 or LMO2, and 
NOTCH1 overexpression 28. The long latency and incomplete penetrance seen with Lck-
Tal1 mice also suggests Tal1 alone is not sufficient to induce disease and that other 
acquired mutations must contribute to leukemogenesis 55. Retroviral insertional 
mutagenesis studies using the Moloney Murine Leukemic Virus (MoMLV) have 
identified Notch1, c-Myc and a dominant negative form of Ikaros as collaborating 
oncogenes in murine Tal1-mediated leukemogenesis 59. Misexpression of Tal1 also 
collaborates with either a p16Ink4a or p19Arf deletion or the overexpression of LIM 
domain only 1 and 2 (Lmo1 and Lmo2), to induce disease in mice 60-62. Lmo proteins 
normally interact with Tal1 as part of a multi-protein complex in erythroid cells and are 
not typically expressed in developing thymocytes 41,60,63. However, LMO proteins are 
also targets of chromosomal rearrangement in patients with T-ALL and have been 
demonstrated to interact with TAL1 in leukemic extracts 41,63-66. In patients, the two 
proteins are often co-expressed 28 and 2 of the 3 children who developed T-ALL due to 
retroviral insertions in the LMO2 locus, as part of the X-linked severe combined 
immunodeficiency (SCID) gene therapy trial, exhibit TAL1 activation 67,68. 
 
Thymocyte development 
 Mature T-cells, like all cells in the hematopoietic system develop from HSCs that 
reside in the bone marrow. HSCs can be divided into two populations 69, a long-term 
subset (LT-HSC), which is capable of extensive and indefinite self-renewal, and a short-
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term population (ST-HSC) that has limited self-renewal capability 70. ST-HSCs give rise 
to the transient multipotent progenitor population (MPP) that can generate common 
myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs) 71. CLPs have 
the potential to mature along either a T or B-cell developmental program 72. Once 
committed to the T-cell lineage, cells within the thymus undergo a tightly controlled 
developmental process that is determined by expression of the CD4 and CD8 co-
receptors (reviewed in 73). Based on expression of CD4 and CD8, developing thymocytes 
can be divided into 4 major subpopulations; CD4 and 8 double negative (DN), CD4 and 8 
double positive (DP), and CD4 or CD8 single positive (SP) (Figure 1).  
  The DN population, the most immature committed thymic progenitors, is made 
up of 4 subpopulations; DN1-4 74. The exact cell type that seeds the thymus is unknown, 
but early thymic progenitors (ETPs) are the earliest known committed T-cell progenitor 
in the thymus 75. ETPs are lineage (lin) and CD25 negative, express CD44, cKit, and 
Sca1, and comprise 80% of the DN1 committed progenitor population 75. The DN1 
population is heterogeneous and is also comprised of the more mature Lin-, CD44+, 
CD25-, cKitlo cells 76,77. Upon appropriate environmental signals the next stage of 
development involves the acquisition of the CD25 co-receptor, which is coincident with 
maturation to the DN2 stage. DN2 progenitors can give rise to two different T lineages; 
αβ and  γδ (reviewed in 76). This lineage choice depends on which TCR becomes 
successfully recombined. Using Rag1 and 2, cells rearrange the TCRδ, TCRγ, or TCRβ 
genes. If progenitors fail to generate an in-frame TCRδ, γ, or β coding sequence, they 
undergo apoptosis. Cells that successfully generate TCRγ and TCRδ proteins, develop 
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into mature γδ T-cells. Cells that generate a successful TCRβ rearrangement continue to 
develop along the αβ lineage.  
 During the DN3 stage, cells lose CD44 expression and rearrange the TCRβ chain 
78. The β selection checkpoint ensures that only cells with an appropriate TCRβ 
rearrangement will differentiate further 79. Here, developing thymocytes pair the TCRβ 
chain with Pre-Tα and CD3 proteins to generate a pre-T-cell receptor (pre-TCR) 80,81.  
 Pre-TCR signaling activates the RAS–mitogen-activated protein kinase (MAPK) 
pathway as well as phospholipase C, which results in activation of several transcription 
factors including Ets-1, Id3, NFAT and NFκB 82-86. Proper pre-TCR signaling arrests 
TCRβ gene rearrangement, provides essential survival signals, and permits further 
differentiation 73,87-89. Cells then lose CD25 expression and progress to the DN4 and 
transient immature single positive (ISP) 90 developmental stages, both of which are 
characterized by extensive proliferation 73. This is followed by the upregulation of CD4 
and CD8 co-receptors and progression to the CD4 and CD8 DP stage. 
  DP thymocytes rearrange the TCRα chain and pair it with a β chain on the cell 
surface forming an αβ TCR. These cells then undergo both positive and negative 
selection 91,92. As many as 95% of thymocytes will not make it through this selection 
process and will die in the thymus 93. Surviving thymocytes then mature to either CD4 or 
CD8 SP cells and enter the periphery. 
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Notch signaling is critical for thymocyte development. 
 T-cell lineage commitment and proper development requires many environmental 
and cell intrinsic signals, including those generated by the Notch family of receptors 
(reviewed in 94). Notch receptors transmit extracellular messages, following ligand 
activation, by translocating to the nucleus and forming a transcriptionally active complex. 
Of the four known Notch receptors, Notch1 is critical for early T-cell development. 
Conditional deletion of Notch1 in the thymus results in reduced thymic cellularity, 
alterations in thymocyte development, and ectopic B-cell development 95,96. Conditional 
deletion of CSL, a Notch binding partner required for transcriptional regulation, also 
results in thymocyte development arrest and B-cell development in the thymus 95,97. 
Consistently, pharmacological inhibition of Notch in fetal thymic organ cultures (FTOC) 
results in B-cell maturation at the expense of T-cell development 98,99. Collectively, these 
studies suggest that Notch1 is essential for T-cell development and these effects are likely 
Notch1/CSL dependent. 
 Conversely, gain of function studies demonstrate that expression of constitutively 
active intracellular Notch1 stimulates DP T-cell development and blocks B-cell 
development in the bone marrow 100. Moreover, transducing bone marrow stromal cells 
with Notch ligands drives T-cell development and inhibits B-cell development in in vitro 
culture assays 101,102. While constitutively active Notch1 causes T-cell proliferation in the 
bone marrow, overexpression of known Notch1 target genes Hes1 and Hes5 fail to 
induce ectopic T-cell expansion in the bone marrow or perturb T-cell maturation in the 
thymus. Hes1 or Hes5 expression does result in a partial disruption of B-cell development 
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103, suggesting that additional Notch1 regulated genes are required to specify T-cell 
development.  
 Normally, Notch ligands, Jagged 1 and Jagged 2 (Jag1, Jag2) and Delta-like 1,3,4 
(Dll1,3,4) are highly expressed in the murine thymus and in the murine bone marrow 
stroma 104-106. Notch receptors are expressed in hematopoietic progenitor cells in the bone 
marrow and on double negative thymic progenitors 105-109. ETPs are the earliest known 
progenitor within the thymus with active Notch signaling. ETPs are DN1 thymocytes but 
also express high levels of Sca1 and c-Kit and resemble more primitive progenitors 
77,110,111. Notch signaling is essential for ETP generation and differentiation 112,113, 
suggesting the critical lineage specification signals that promote T-cell commitment may 
be received upon thymic entry.  
 Notch1 is not only required for lineage commitment, but is also essential for DN 
thymocyte differentiation. During early thymocyte development, Notch1 expression is 
highest in early DN thymocytes and increases as cells progress to the DN3 stage of 
development. Following progression to the DN4 and DP stage of development Notch1 
expression is downregulated 105,114, suggesting precise regulation of Notch1 expression 
during the DN3 – DN4 progression is critical. Consistently, conditional deletion of 
Notch1 in developing thymocytes results in a partial DN3 differentiation block. This 
developmental arrest is in part due to impaired β chain rearrangement 115-117. Notch1 is 
also required for proper pre-TCR signaling, which is essential for the proliferative burst 
and subsequent maturation of thymocytes 118. Some studies suggest that Notch1 also 
directs αβ T-cell fate at the expense of γδ development 117,119,120 and CD4 versus CD8 SP 
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cell fate, however those subjects remains highly controversial 97,116,121-123. Lastly, Notch 
signaling is also involved in both T helper 1 and 2 (Th1 and Th2) cell differentiation. 
Notch1 is required for Th2 differentiation and this is mediated by IL-4 signaling and 
Gata-3 upregulation 124,125. While gain of function studies suggest Notch signaling also 
drives Th1 development 126, it remains unknown if Notch signaling is essential for the 
Th1 response 124,127. 
 Other Notch receptors may also function during early thymocyte development. 
Notch3 and to a lesser extent Notch2 are also expressed in early DN thymocytes 105. 
Notch3 over-expression in early thymocyte development leads to phenotypes similar to 
that seen when Notch1 is overexpressed 128. However, further studies reveal that unlike 
Notch1-deficient mice, Notch2- or Notch3- deficient mice do not display defects in early 
T-cell development 129,130. These data suggest that Notch1 is a critical regulator at this 
developmental stage.  
  
The Notch signaling pathway 
Notch was first identified in 1917 through a loss of function phenotype that 
resulted in notched wings in Drosophila melanogaster 131. Since that discovery, further 
examination of Notch signaling in Caenorhabditis elegans (C. elegans), vertebrates, and 
mammals has proven the pathway to be more complex. There are four members of the 
mammalian Notch family (Notch1-4), each are single pass transmembrane receptors with 
highly conserved protein domains 132,133. In addition, there are 5 mammalian Notch 
ligands; Jag1,2 and Dll1,3,4. Notch ligands are structurally very similar, however Jag 
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ligands contain a greater number of epidermal growth factor (EGF) repeats and a 
cysteine-rich region close to the membrane that are not found in Dll ligands 134. It is 
through the four receptors and 5 ligands that mammalian Notch signaling regulates cell 
fate, differentiation, proliferation and survival in a diverse array of biological processes 
from angiogenesis to hematopoiesis.  
Unlike the two Notch homologs in C. elegans (Lin-12 and GLP-1), which are 
functionally redundant 135, mammalian Notch proteins have both overlapping and unique 
roles in normal development and disease.  Structurally, however, Notch proteins are 
similar and contain two major subunits; the extracellular subunit (NEC) and the 
transmembrane subunit 34 136. The NEC domain contains 29-36 EGF repeats, which bind 
Notch ligands 137, and a negative regulatory region (NRR). The NRR consists of three 
LIN12/Notch repeats and a heterodimerization domain (HD), which prevents ligand 
independent signaling. The NTM subunit contains a RAM domain and ankyrin (ANK) 
repeats, which are essential for protein interactions 138-141. A full transactivation domain 
(TAD) is found in the NTM subunit of Notch1 and 2 proteins, however, Notch3 and 4 
proteins contain significantly shorter TAD regions 138,142. The NTM subunit also contains 
a C-terminal Pro-Glu-Ser-Thr (PEST) domain that is ubiquitinated to regulate Notch 
protein stability 143.  
Generation of the mature Notch receptor requires three proteolytic cleavage 
events (Figure 2). The first is by a furin-like protease in the Golgi, which results in the 
cleavage of the NTM and the NEC 136. These two domains then become noncovalently 
associated and the receptor is shuttled to the membrane. Once at the membrane the 
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second and third cleavage events are initiated by binding to membrane-bound ligands; 
Jag or Dll 144-146. Cleavage by a TNF-α converting enzyme (TACE), a member of the a-
disintegrin and metalloprotease (ADAM) family, occurs first and cleaves Notch close to 
the transmembrane domain 147. This cleavage creates a short-lived transmembrane 
associated protein that is then cleaved at valine 1744 by a γ-secretase protein complex 148. 
The γ-secretase complex is a multiprotein complex containing Presenilin, Nicastrin, 
Presenilin enhancer 2 (Pen-2), and Anterior pharynx defective 1 (Aph-1) 148-152. 
 The result of these cleavages is the release of the intracellular form of Notch 
(ICN) from the membrane. ICN then translocates to the nucleus where it binds to the 
helix-loop-helix transcription factor CSL (CBF1/RBP-J in mammals Suppressor of 
Hairless in Drosophila and Lag1 in C.elegans) and recruits coactivators; Mastermind-like 
1 (MAML) and CBP/p300 141,153,154. In the absence of ICN binding, CSL binds the 
corepressor complex containing; KyoT2, CIR, N-CoR/SMRT, SKIP, Sin3A, SAP18, 
SAP30, RbAp46/48 and HDAC and inhibits transcription 155-160. However, ICN binding 
to CSL replaces corepressors and recruits coactivators, which facilitates transcription 161. 
The ICN, CSL, MAML, p300 complex then binds to CSL consensus sites 
(TGGGAA) within the promoter region of target genes. Targets including, Notch1, Hes1, 
Deltex1, Notch3, Nrarp, Pre-Tα, Cyclin D1, p21, c-Myc, CDK4/6, CD25 are directly 
regulated by Notch1 59,162-164. 
 
 
 
  
 
14 
The regulation of the Notch signaling pathway. 
Precise Notch signaling is critical for a number of biological processes including 
apoptosis, proliferation, differentiation, and self-renewal. Therefore Notch signaling is 
tightly regulated by a variety of mechanisms. One mechanism is by the Fringe family of 
glycosyltransferases. There are three Fringe family members in mammals; Lunatic fringe, 
Manic fringe, and Radical fringe 165,166. Fringe family members contribute to Notch 
pathway regulation by modifying the EGF repeats on the extracellular domain of the 
Notch receptor 165. Although the role of EGF modification is not entirely understood, one 
function includes controlling Notch ligand/receptor binding specificity. For example, 
modification of Notch1 by Lunatic fringe specifically promotes Notch1/Dll interactions 
and inhibits Jag1 mediated signaling 167. 
Notch protein stability is also regulated though ubiquitin modification by Itch, 
Numb, and Fbxw7. Itch, a HECT-domain E3 ubiquitin ligase, interacts with membrane-
bound Notch1 both in vitro and in vivo 168 and targets Notch1 for a lysosome-degradation 
pathway 169. Numb, a membrane-associated protein, interacts with ITCH to promote 
ubiquitination of membrane-bound Notch1 and also mediates degradation of the 
intracellular domain following ligand dependent cleavage 170. 
Fbxw7 (also known as Sel-10, hCdc4), an F-box containing protein, is one of the 
four subunits of ubiquitin protein ligase complex called SKP1-cullin-F-box (SCFs) 171. 
Fbxw7 interacts with substrates via its WD40 repeats following phosphorylation of the 
substrate within the Cdc phosphodegrons (CPDs) 172,173. Following phosphorylation of 
Notch within the PEST domain by CycC:CDK8, Fbxw7 specifically binds and recruits 
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the ubiquitin ligase SCF complex to PEST domain 174. The addition of ubiquitin 
subsequently targets the protein for degradation by the proteosome 175-179. Fbxw7 is a 
haploinsufficient tumor suppressor that has a number of cellular targets besides Notch 
receptors, including Cyclin E, Myc, c-Jun, and mTOR 180-182. 
Notch signaling is also regulated by ligand and receptor availability (reviewed in 
183). Both Notch ligands and receptors have distinct patterns of expression that limit 
Notch activation. Notch1 is widely expressed throughout a number of tissues including; 
the brain, liver, heart, lung, kidneys, stomach, intestine, bone marrow, skeletal muscle, 
spinal cord, eye, and thymus. Notch2 expression is also broad, as it is found in brain, 
liver, kidney, and stomach. Notch3 and Notch4 expression however, are more restricted. 
Notch3 is found expressed in vascular smooth muscle, the central nervous system, and 
hematopoietic cells, while Notch4 expression is limited to vascular endothelial cells. As 
mentioned previously, some structural variability is observed among Notch receptors, in 
that Notch1 and Notch2 included a full-length TAD, while Notch3 and Notch4 have 
truncated or the absence of the TAD entirely 138,142. Presence or absence of a TAD may 
affect Notch signal strength and lead to activation of specific target genes. Therefore, the 
distinct pattern of expression of each of the 4 Notch receptors could also be a mechanism 
to regulate the effects of Notch signaling. 
 
The role of Notch signaling in development. 
Notch signaling is critical for a number of cellular functions both embryonically 
and postnatally. During embryogenesis, Notch receptors and ligands are essential and 
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have non-redundant roles. Targeted deletion of Notch1 and Notch2 results in embryonic 
lethality at day 11.5 due to severe defects in somitogenesis and vasculogenesis  184,185. 
Consistently, deletion of Notch ligands Dll1, Dll4, or Jag1 also result in embryonic 
lethality during E9.5–E12.5 186,187. While, Notch3 null and Notch4 null mice survive, 
severe defects in vascular development are also observed 188.  In humans, the requirement 
for proper Notch signaling is demonstrated in Alagille syndrome, an autosomal-dominant 
disorder, characterized by JAG1 deletions and severe abnormalities of liver, heart, eye, 
skeleton, and kidneys 189. Cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL), a hereditary stroke disorder resulting 
from blood vessel degeneration, is associated with NOTCH3 mutations 190,191. These 
syndromes highlight the importance of Notch signaling throughout mammalian 
development.  
Studies in Drosophila and C. elegans demonstrate that one function of Notch is 
the regulation of lineage choice. Notch promotes lineage specification via lateral 
induction or lateral inhibition (reviewed in 132). Lateral induction implies that some cells 
express Notch ligands (potential for higher Notch signaling) and other cells express 
Notch receptors (potential for lower Notch signaling). Through cell-to-cell interactions, 
some cells generate more Notch signaling activity, which induces a certain cell fate. The 
other proposed mechanism, lateral inhibition, suggests that groups of precursors express 
both Notch ligands and receptors. However, by a mechanism that is currently unknown, 
some cells within the group acquire higher Notch signaling than the others. This effect 
can be amplified, as Notch signaling has the potential to feedback and inhibit ligand 
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expression. Eventually distinct groups of cells with differing levels of Notch signaling are 
formed, dictating different lineage choices. 
Notch signaling is important for lineage choice decisions in a variety of cellular 
contexts (reviewed in 132). In the skin, Notch1 is essential for hair follicle development 
from precursor cells 192,193. Targeted deletion of CSL in the skin results in hair loss and 
epidermal hyperkeratinization 194, suggesting Notch/CSL promote hair formation and 
block epidermal differentiation. In vascular development, Notch signaling specifies 
arterial versus venous endothelial cell fate decisions. It is hypothesized that the default 
pathway of the endothelial precursor cell is a venous cell fate. However, Dll4/Notch 
signaling directs endothelial cells to an arterial fate 195,196. Consistently, expression of 
Notch receptors and ligands are found restricted to arteries 90,197. Studies using CSL null 
mice and evaluation of patients with NOTCH3 mutations demonstrate that loss of 
Notch/CSL signaling results in severe arterio-venous-malformations 198. 
In the intestine, Notch signaling also promotes cell lineage specification. The 
intestinal epithelium is comprised of enterocytes, endocrine, paneth, and goblet cells that 
are all derived from multipotent stem cells located in the intestinal crypts. Enterocytes, 
which comprise the majority of the intestinal epithelium, have an absorptive function and 
can differentiate from crypt stem cells following signals from Notch target gene, Hes1 
199. Notch signaling also inhibits the differentiation of mucous secreting goblet cells from 
crypt stem cells by repressing Klf4 200. Consistent with these data, pharmacological 
inhibition of Notch signaling can result in a differentiation shift of crypt stem cells from 
the enterocyte fate to the goblet cell fate 201. 
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The Notch signaling pathway also regulates functions commonly co-opted in 
malignancy, such as proliferation and self-renewal. Self-renewal is defined as the  
capacity of cells to produce daughter cells indefinitely, while retaining the ability to 
produce more differentiated progeny, through asymmetric division (reviewed in 202). To 
date a number of pathways, including the Notch pathway, have been implicated in 
regulating stem cell self-renewal. Specifically, roles for Notch1 in self-renewal have been 
described in epithelial, neuronal, intestinal, and mammary stem cells 201,203-206. In 
neuronal stem cells (NSC), Notch1 signaling is required for stem cell maintenance, as 
CSL or Notch1 deficient mice have a significant reduction in NSCs204,205. Similarly, in the 
intestinal epithelium, CSL deficient mice have a decrease in stem cell number and 
conversely, constitutive expression of Notch1 results in intestinal stem cell hyperplasia 
203.  
A role for Notch signaling in HSCs has also been proposed. While it is clear that 
Notch1 is essential for the generation of hematopoietic stem cells in the embryo 207-209, 
the role of Notch1 in HSC maintenance remains controversial. Expression of Notch 
ligands or intracellular Notch1, increases self-renewal and blocks differentiation of HSCs 
210. Constitutive Notch1 expression in murine HSCs resulted in a cytokine dependent 
HSC cell line that retains both myeloid and lymphoid pluripotency 211. However, 
blocking Notch signaling in HSCs via overexpression of a dominant negative form of the 
Notch coactivator Mastermind-like 1 (DnMAML), or using CSL deficient HSCs showed 
no defect in HSC self-renewal capabilities 212. Consistent with this finding, Notch1/Jag1 
double knockout mice appear to have normal HSC function 213. One possible explanation 
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for these conflicting results is that Notch receptors have functionally redundant roles in 
promoting HSC self-renewal or regulate self-renewal of HSCs via a CSL independent 
pathway. It is also possible that high levels of Notch1 signaling achieved in gain of 
function studies may alter HSC function. Thus, deregulated Notch1 signaling may confer 
self-renewal capabilities on stem cells or progenitors and thereby contribute to 
malignancy.  
 
NOTCH1 is the most frequently mutated gene in T-ALL . 
NOTCH1 was first implicated in T-ALL through a rare chromosomal 
translocation t(7:9)(q34:q34.3) originally described in 1991 214. In less than 1% of 
patients with T-ALL, the 3’ region of NOTCH1 (chromosome 9) is translocated to the 
TCRβ locus (chromosome 7). This translocation results in a truncated, constitutively 
active form of NOTCH1 capable of ligand independent signaling. Expression of this 
constitutively active protein transforms cells in vitro 215 and mice reconstituted with 
intracellular NOTCH1 expressing bone marrow develop a T-ALL-like disease 216. 
Additional experiments demonstrate that expression of activated NOTCH1 in the murine 
thymus also results in T-cell neoplasms 217. Mutational analyses demonstrated that the 
ankyrin domain (ANK), nuclear localization sequences (NLS), and transcriptional 
activation domain (TAD) of NOTCH1 are each required for leukemic transformation 218. 
Taken together these studies confirmed that constitutively active NOTCH1 is oncogenic 
and contributes to leukemic transformation.  
Since the discovery of the t(7:9)(q34:q34.3) translocation, gain of function 
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mutations affecting NOTCH1 have been detected in approximately 70% of T-ALL 
patients 219-224. NOTCH1 mutations in the HD and/or PEST domains are the most 
common and occur in 50% of T-ALL patients 224. HD mutations cause an amino acid 
sequence change that results in ligand independent cleavage by the TNF-α converting 
enzyme 225. C-terminal PEST domain mutations appear less frequently and are generally 
deletions or insertions that truncate the protein 224. As ubiquitination of the C-terminal 
PEST domain targets NOTCH1 for degradation by the proteasome, deletion of the PEST 
domain results in increased NOTCH1 stability 176. Interestingly, 18% of T-ALL patients 
harbor HD mutations and PEST mutations in the same NOTCH1 allele, which results in a 
10-fold increase in reporter activity compared to NOTCH1 alleles containing only HD or 
PEST mutations 224. Recently, internal tandem duplications within the juxtamembrane 
domain (JME) of NOTCH1 were observed in an additional 3% of T-ALL patients 223. 
These mutations facilitate metalloprotease cleavage and result in ligand independent 
activation of NOTCH1 223. Inactivating mutations in the NOTCH1 E3 ligase, FBXW7, are 
also found in 8.6% of primary T-ALL samples. These heterozygous missense mutations 
occur within the substrate-binding domain of FBXW7 and reduce substrate recognition, 
resulting in increased levels of intracellular NOTCH1. 
 Unlike intracellular NOTCH1, the NOTCH1 alleles with either HD or PEST 
mutations only, do not generate sufficient levels of NOTCH1 expression to initiate 
leukemia in bone marrow transplantation assays 226. However, these alleles can accelerate 
K-Ras induced T-ALL development 226. These data suggest that many of the gain of 
function NOTCH1 mutations commonly seen in T-ALL are most likely secondary or 
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cooperative events in leukemia. 
Other Notch family members have been implicated in leukemogenesis, but to a 
lesser extent than NOTCH1. While no mutations or translocations affecting NOTCH2 or 
NOTCH3 have been described as of yet, intracellular NOTCH2 is capable of 
transforming rat kidney cells that had been previously immortalized by E1A (RKE cells) 
in vitro, albeit less efficiently than NOTCH1 215. A transgenic mouse model that 
expresses constitutively active Notch3 in thymocytes also develops T-cell leukemia 128. 
NOTCH3 overexpression has also been described in relapsed human T-ALL samples 227. 
In contrast, no association with NOTCH4 has been demonstrated in T-ALL.  
 
Notch1 mutations are frequent in mouse T-ALL models. 
In a number of mouse T-ALL models, Notch1 mutations are common cooperating 
events 228-231. In the Lck-Tal1 T-ALL model, spontaneous Notch1 mutations are detected 
in 74% of the resultant tumors 230. Mutations predominantly occur in the PEST regulatory 
region, resulting in a truncated, stable form of Notch1 (91.5%), and HD mutations are 
rare (8.5%) 230. The reason for the difference in the type of NOTCH1 mutations detected 
among murine and human T-ALL samples is unclear, but might indicate that murine T-
cell leukemic blasts still rely on ligand activation, or harbor an as yet unknown mutation 
that promotes ligand independent signaling. Murine Tal1 tumors were also analyzed for 
the presence of mutations in Notch2, 3, and 4. However when these regions were 
sequenced in 28 tumors, no mutations were found. These data suggest that like human T-
ALL, there is preferential activation of Notch1 in Tal1 induced leukemogenesis 230. 
  
 
22 
 
 NOTCH1 mediates leukemic growth by directly regulating c-MYC expression 
The prevalence of NOTCH1 mutations in T-ALL suggests that aberrant Notch 
signaling may be required for leukemic growth and/or survival. To test a requirement of 
NOTCH1 for leukemic growth, T-ALL cell lines were cultured with γ-secretase 
inhibitors (GSIs), and cell proliferation and viability were measured. GSIs inhibit Notch 
cleavage by the γ-secretase complex, and therefore prevent the generation of intracellular 
Notch. GSI treatment caused a G1 cell cycle arrest and/or apoptosis in both murine and 
human T-ALL cell lines 224,230,232,233.  In addition, GSI treatment decreased intracellular 
NOTCH1 expression and reduced NOTCH1 target gene expression 224,230,233.  Although 
the γ-secretase complex has a number of substrates, including Notch ligands, ErbB4, 
CD44, Growth hormone receptor, N- and E-cadherins, and Amyloid precursor protein 234-
237, the G1 arrest/ apoptosis observed in human and mouse T-ALL cell lines can be 
rescued by retroviral expression of intracellular Notch1 (ICN1) prior to GSI treatment 
59,224. Additionally, similar effects on leukemic growth are also observed when Notch 
signaling is inhibited via overexpression of a dominant negative form of the Notch 
coactivator Mastermind-like 1 (DnMAML) 233. Collectively, these data demonstrate that 
Notch1 is required for leukemic growth and suggest GSIs inhibit leukemic growth via 
Notch1 inhibition. 
 Although Notch1 has clearly been shown to be required for leukemic growth in 
vitro, how Notch1 mediates transformation is unknown. Retroviral expression of many 
Notch1 regulated genes, such as Hes1, Hes5, and Cyclin D3, fail to rescue leukemic cells 
  
 
23 
from the effects of Notch inhibition, indicating that these target genes are not sufficient 
for leukemic growth 233. Gene expression profiling has identified c-MYC as a novel 
direct transcriptional target of NOTCH1 in both murine and human T-ALL cells 59,163,238. 
Importantly, c-MYC, like ICN1, is sufficient to fully rescue many murine and human T-
ALL cell lines from the effects of Notch1 inhibition in vitro 59,163. c-Myc deletion in 
mouse T-ALL cells also inhibited leukemic growth, suggesting that c-Myc may be 
required for Notch1 leukemic growth in vivo 239. 
 However, unlike ICN1, c-MYC is unable to rescue 2 of 10 murine and 2 of 5 
human T-ALL cells lines from the effects of Notch1 inhibition59,163, suggesting other 
Notch1 target genes contribute to leukemogenesis. Additional studies have identified a 
number of cell cycle mediators including p27, CYCLIN D3, CDK4, and CDK6 as genes 
regulated by NOTCH1 in T-ALL cells 164,240. While these genes likely contribute to 
leukemic growth, overexpression of these targets provides only a partial rescue from GSI 
induced G1 arrest in human T-ALL cell lines 164.  One goal of this thesis research is to 
identify additional Notch1 regulated genes in T-ALL and to evaluate their role in 
leukemic growth and survival. Data presented in Chapters 2 and 3 of thesis establish that 
Notch1 positively regulates Lef1 and the AKT/mTOR pathway, both of which are 
important for murine leukemic growth. 
 
Notch1 directly regulates Lymphoid enhancing factor 1 (Lef1) expression in murine 
T-ALL cells.  
Lymphoid enhancing factor 1 (Lef1) is a member of the T-cell factors (Tcf) 
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family of DNA binding transcription factors 241,242. The four family members (Lef1, Tcf1, 
Tcf3, Tcf4) are highly homologous and contain four critical protein domains; β catenin, 
cysteine-rich domain (CRD), high mobility group binding (HMB) domains, and 
alternatively spliced C-terminal tails (reviewed in 243). The most N-terminal domain is the 
β catenin binding domain, which shares 60% homology between all Tcf family members. 
The CRD domain is the most diverse among family members, sharing 15-20% homology, 
and is critical for recruitment of the corepressor, Groucho. The HMG domain is highly 
conserved among family members (95-99% homologous) and is essential for DNA 
binding. The functions of the C-terminal tails is not well understood but are thought to 
contribute to specific regulation of target genes. Two LEF1 isoforms have been 
described, a full-length 54kDa nuclear protein and a truncated protein that lacks the HMB 
binding domain 244. 
 Lef1 is a integral component of the highly conserved WNT/β catenin signaling 
pathway (reviewed in 245). WNT proteins are secreted glycoproteins that facilitate cell-to-
cell interactions by binding to membrane bound receptor complexes. In the absence of 
WNT signaling, β catenin is phosphorylated and restricted to the cytoplasm. In this case, 
Lef1 functions as a transcriptional repressor through interactions with Groucho246,247. 
Upon WNT pathway activation, β catenin is dephosphorylated and translocates to the 
nucleus where it binds Lef1 or other Tcf family members, and activates transcription 248. 
Lef1 also contributes to transcriptional regulation by bending DNA and providing 
essential contacts between transcription factors 249. Transcriptional target genes of Lef1 
include, Cyclin D1, Survivin, c-Myc, Myc Binding Protein (Mycbp) and the Dll1 250-253. 
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Tcf family members are critical for a number of diverse, context dependent 
processes including embryogenesis, intestinal and skin stem cell maintenance, 
granulopoiesis, hair follicle formation, B-cell progenitor proliferation, and thymocyte 
development 254-256. In murine thymocyte development, Lef1 and Tcf1 are highly 
expressed and appear to have partially redundant roles. While Lef1 deficient mice have 
normal T-cell development, and Tcf1 deficient mice have an incomplete DN1, DN2, and 
ISP block, Lef1/Tcf1 double knockout mice have a complete block at the ISP stage of 
early thymocyte development 257. This developmental stage is a period of thymocyte 
progenitor expansion, suggesting Lef1 may contribute to thymocyte expansion possibly 
through enhancing c-Myc levels. 
 In addition to normal lymphopoiesis, Lef1 has been implicated in 
leukemogenesis.  Mice reconstituted with Lef1 expressing bone marrow developed 
alterations in myeloid and lymphoid development 258. These mice also develop B-ALL or 
AML, revealing that Lef1 misexpression contributes to leukemogenesis. Consistently, in 
primary human acute leukemia samples, LEF1 expression is often higher than normal 
bone marrow or lymphocyte controls 259. While Lef1 has been implicated in B-ALL and 
AML, whether Lef1 is important in T-ALL remains unknown. In Chapter 2 of this thesis, 
we demonstrate that Lef1 is a direct target of Notch1 in murine T-ALL and examine its 
role in leukemic growth. 
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Notch1 activates the PI3k/Akt/mTOR pathway in normal thymocyte development 
and in murine T-ALL. 
Phosphatidylinositol 3-kinase (PI3K) phosphorylates phosphoinositide lipids to 
promote a number of critical cellular functions including proliferation, survival and 
cellular movement. There are four classes of PI3Ks (1A,1B, II, III), which are classified 
based on complex subunits 260. Class I PI3Ks, the most studied, are activated by 
extracellular signals and oncogenes, such as Ras 261 (Figure 3). Once activated PI3K 
phosphorylates phosphoinositides and generates phosphatidylinositol-3,4-bisphosphate 
(PI(3,4)P2) and phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5,)P3). PI(3,4,5,)P3 is the 
major mediator of downstream PI3K signaling and is regulated by phosphatases  
including, phosphatase and tensin homolog (Pten) and inositol polyphosphate-5-
phosphatase D (Ship1/2)262,263. Once PI(3,4,5,)P3 is generated, it promotes the 
translocation of Akt to the cellular membrane, which facilitates its activation by kinases 
including phosphoinositide-dependent kinase 1 (Pdk1), the mTORC2 complex, and Akt 
itself 264-268. Once activated, Akt promotes survival and cell growth through the 
phosphorylation of a number of downstream targets, including, Bad, Glycogen synthase 
kinase-3β (Gskβ), Forkhead transcription factors (Foxo), and the mammalian target of 
rapamycin (mTOR) 269-273. 
mTOR is a protein kinase that is highly conserved from yeast to human. TOR was 
first identified through a mutational study in yeast that resulted in resistance to the 
macrolide antibiotic; rapamycin 274. The mammalian form, mTOR, was later identified 
based on its binding capability to rapamycin 275-278. mTOR is a member of two functional 
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protein complexes; mTORC1 and mTORC2 (Figure 3)(reviewed in 279). mTORC1, the 
rapamycin sensitive complex, is involved in protein translational initiation through 
phosphorylation of downstream targets such as; eukaryotic translation initiation factor 4E 
binding protein 1 (4EBP-1), ribosomal protein S6 (S6RP), and ribosomal protein S6 
kinase (p70 S6 K) 280,281. The mTORC2 complex is relatively nutrient and rapamycin 
insensitive and can activate the Akt signaling pathway through phosphorylation 282,283.  
mTOR signaling is critical for a number of diverse cell functions including 
protein translation, autophagy, cellular growth, and metabolism (reviewed in 284). mTOR 
signaling responds to environmental signals and are generally regulated by growth factors 
and amino acid availability or by mitogens through the Ras/MEK/ERK pathway 279. 
Stimulation of the PI3K/Akt pathway also activates mTOR signaling by directly 
phosphorylating and inhibiting Tsc1/2 protein complex, which is a negative regulator of 
mTORC1 (reviewed in 284).  
When activated, one of the functions of the mTORC1 complex is protein 
translation initiation through the phosphorylation and inhibition of 4EBP-1 285. Protein 
translation is initiated when the eukaryotic translation initiation factor (eIF4F) complex, 
composed of eIFAE, eIF4G, eIF4A, is assembled and recruited to the 5’ cap structure of 
mRNA (reviewed in 286). Assembly of this complex is tightly controlled. Under 
conditions that require reduced protein translation, 4EBP-1 binds to eIF4E and prevents 
its association with eIF4G and eIF4A. However, upon mTORC1 activation, 4EBP-1 is 
phosphorylated and inhibited 285. This allows the formation of the eIF4F complex and cap 
dependent translation. mTOR also regulates translation through phosphorylation and 
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activation of target p70 S6 K 287. P70 S6 K activation then phosphorylates a number of 
downstream targets including S6RP. Activation of S6RP promotes the translation of 
mRNAs that primarily encode ribosomal proteins and members of the translational 
machinery. 
 Since the mTOR signaling pathway is a key regulator of protein translation, cell 
growth, and metabolism, it is often misregulated in cancer (reviewed in 288). Often, the 
upstream regulators of mTOR signaling are deregulated by growth factor receptor 
upregulation, gain of function mutations affecting PI3K/Akt directly, or through 
deregulation of Pten. Interestingly, many mouse models of tumorigenesis driven by Pten 
deletion or constitutively Akt activation, are sensitive to mTOR inhibition by rapamycin 
289,290. These studies suggest that mTOR is a critical factor in PI3K-mediated 
tumorigenesis.  
In addition to classical regulation by growth factors or pathways such as Ras, 
there is growing evidence that, Notch1 may also regulate the PI3K/Akt/mTOR pathway. 
During the DN3 to DN4 transition in thymocyte development, Notch1 provides critical 
proliferative and survival signals following the generation of a productive pre-TCR. 
Constitutively activated Akt can rescue early double negative thymocytes from apoptosis 
associated with Notch inhibition and can restore the ability of cells to undergo β selection 
in the absence of Notch signaling 118. These findings suggest Notch1 promotes double 
negative thymocyte survival through activation of the PI3K/Akt pathway. These data 
have major implications for T-ALL and suggest Notch1 may mediate leukemic survival 
by activating the Akt pathway. The work presented in Chapter 3 of this thesis 
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demonstrates that the AKT/mTOR pathway is aberrantly activated in murine T-ALL and 
its activation is in part mediated by Notch1 signaling. We also demonstrate that the 
mTOR pathway mediates essential survival signals in murine T-ALL cell lines. 
Moreover, we demonstrate that Notch and mTOR pathway inhibition reduces human T-
ALL growth in vivo.  
 
Analysis of leukemic initiating cell population in T-ALL 
 50% of TAL1+ T-ALL patients relapse following chemotherapy 28. Relapse may 
occur because genomic instability and diversity among the malignant cells contributes to 
drug resistance and disease relapse. Relapse may also occur because malignancies harbor 
a subset of tumor cells, leukemia-initiating cells (L-ICs), that are inherently resistant to 
conventional treatment. In many hematopoietic malignancies, including AML and 
chronic myelogenous leukemia (CML), there is evidence of a L-IC population. Although 
the genes and pathways involved in L-IC biology are relatively unknown, evidence 
suggests that pathways critical to the maintenance of normal stem cells, such as the Notch 
pathway 201,203-206, maybe required for L-IC maintenance.  
 L-ICs were first identified in AML 291,292 and are described as a subpopulation of 
cancer cells that have the unique ability to initiate disease. Like normal stem cells, L-ICs 
can self-renew and give rise to more L-ICs (daughter cells) that retain increased 
proliferative capacity (reviewed in 202). L-ICs also have the potential to divide and 
differentiate into progenitor cells with finite proliferative capacity. These progenitor cells 
often comprise the bulk of the tumor cells and are thought to have diminished initiating 
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potential. Importantly, L-ICs, like normal HSCs, have been shown to be resistant to 
apoptotic stimuli, and may also express increased levels of ATP-associated transporters 
which renders cells relatively resistant to conventional chemotherapy 293,294. 
  For most AML subtypes, human leukemic cells enriched in the capacity to 
initiate disease in nonobese diabetic/ severe combined immunodeficient (NOD/SCID) 
mice express CD34 and lack CD38 expression, which is immunophenotypically similar 
to primitive hematopoietic stem cells 291,292. This suggests that AML is organized in a 
hierarchical manner, like normal hematopoiesis, and that L-ICs arise due to mutations 
within HSCs. The finding that hematopoietic or adult stem cells are enriched in L-IC 
activity is probable because of the inherently long lifespan of stem cells that could permit 
the acquisition of numerous mutations required for transformation. In addition, stem cells 
are already capable of both self-renewal and differentiation, which are critical for tumor 
initiation.  
 However, recent studies using mouse models of leukemia suggest that committed 
progenitors may also be the targets of transformation and harbor L-ICs. While committed 
progenitors may have the ability to proliferate and differentiate, they do not have the 
ability to self-renew. Therefore, committed progenitors must acquire the ability to self-
renew through transformation events. In CML, Gsk3β missplicing leads to enhanced β 
catenin activity that results in aberrant self-renewal of granulocyte-macrophage 
progenitors (GMPs) 295,296. Inhibition of β catenin through Axin overexpression inhibits 
the ability for GMPs to initiate leukemia in recipient mice 295. Similarly, in mouse models 
of AML, numerous studies have demonstrated that fusion proteins such as MLL-ELL, 
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MLL-GAS7, MLL-AF9, MOZ-TIF2, and Cbfβ-SMMHC can transform restricted 
myeloid progenitors that lack self-renewal capacity 297-301. Hence these studies 
demonstrate that L-ICs may arise from transformation events occurring in either the HSC 
or in the committed progenitor compartments. 
  While the presence of L-ICs has been well documented in AML and CML, there 
is less evidence implicating L-ICs in ALL. A L-IC population has recently been 
identified in pediatric T-ALL patients 302,303 and GSI treatment of a few T-ALL patients 
reduced engraftment in NOD/SCID mice 302. Data presented in Chapter 4 of this thesis 
demonstrate that clonal mouse T-ALL tumors are phenotypically heterogeneous, 
containing immature DN3-like and DN4-like thymic progenitors and differentiated DP 
and/or SP leukemic blasts.  Importantly, the DN3/DN4 progenitors are Notch active and 
are enriched in disease initiating potential, whereas mice injected with DP leukemic 
blasts failed to develop leukemia. These data suggest T-ALL, like AML and CML, 
harbors a leukemic stem cell population. 
 
Targeting the Notch pathway in T-ALL 
 The dependence of T-ALL cell lines on Notch signaling 224,230,232,233, and the 
emerging role of the Notch pathway in the maintenance of L-ICs 302, make this pathway a 
potential therapeutic target. To date there are a number of proposed mechanisms to 
inhibit Notch signaling. One is to block cleavage events required for Notch receptor 
processing through the use of GSIs, as mentioned previously, or inhibitors that affect the 
enzymatic activity of the ADAM metalloproteases 304,305. Another approach is to interfere 
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with Notch receptor and ligand binding using monoclonal antibodies (reviewed in 306). 
Notch signaling could be inhibited in the nucleus, using small molecules that mimic 
dominant negative Mastermind-like 1 (DnMAML) or by using siRNAs to specifically 
disrupt the protein-protein interactions that are required for Notch-dependent 
transactivation 307,308.  
 To date GSIs and monoclonal antibodies to the Notch receptor are being tested 
clinically 306,309 however systemic inhibition of Notch has been associated with several 
toxicities, including secretory diarrhea due to goblet cell metaplasia of the small intestine, 
reversible thymic suppression, and hair pigmentation and loss 200,310. A phase 1 clinical 
trial opened to test the effects of GSIs on 8 relapsed leukemia and lymphoma patients 309. 
The patients were administered GSI continuously and because of associated toxicities, the 
trial closed prematurely before the clinical efficacy of GSIs could be evaluated. The work 
presented in Chapter 3 of this thesis tests whether in vivo GSI administration has anti-
leukemic activity in preclinical mouse models. We developed an intermittent dosing 
regimen to minimize toxicities and demonstrated that Notch1 inhibition limits mouse and 
human leukemic growth in vivo. The work presented in this thesis also explores the 
possibility of using GSIs in combination with other anti-cancer drugs as a possible 
treatment regimen for T-ALL. 
 In summary, the work presented in this thesis aims to determine the mechanisms 
of Notch1 mediated leukemogenesis in the mouse. Data presented in Chapter 2 and 3 of 
this thesis identify that in murine T-ALL, Notch1 regulates Lef1 and the Akt/mTOR 
pathway. Data presented in Chapter 3 of this thesis also examine the possibility of GSIs 
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as monotherapies or as a combination therapy for extended periods in vivo. Lastly, the 
work in Chapter 4 of this thesis provides evidence that T-ALL is driven by L-IC 
population and identifies that this population is enriched within committed thymic 
progenitors.  
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Figure 1.  Scheme of T-cell development. Thymocyte development proceeds via 
discrete stages with DN progenitors giving rise to DP (CD4+ and CD8+) thymocytes that 
differentiate into CD4 or CD8 SP thymocytes. The DN progenitors can be distinguished 
by CD25 and CD44 staining pattern with DN1 stage consisting of (CD44+, CD25-), DN2 
(CD44+, CD25+), DN3 (CD44-, CD25+), and DN4 (CD44-, CD25-) cells. Fluorescence 
intensity, as measured by flow cytometry on an arbitrary scale, is indicated for each 
marker. (Figure adapted from Ceredig and Rolink, Nat. Rev. Immunol. 2002). 
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Figure 2.  Scheme of the Notch signaling pathway. There are 4 mammalian Notch 
receptors (Notch 1-4) and five ligands (Jag 1,2 and Dll1,3,4). Notch signaling is triggered 
upon ligand and receptor interaction, which induces two proteolytic cleavages; the first is 
by metalloproteases and the second is by the γ-secretase complex. Cleavage by the γ-
secretase complex results in the release of the intracellular domain of Notch that 
translocates into the nucleus and associates with CSL. The association of intracellular 
Notch and CSL leads to the recruitment of coactivators (MAML, p300) and forms a 
transcriptionally active complex. Release of ICN can be inhibited with γ-secretase 
inhibitors (GSIs). (Figure was adapted from Nam et al. Current Opinion in Chemical 
Biology 2002). 
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Figure 3. Model of the PI3K/Akt/mTOR signaling pathway. Extracellular signals and 
RAS regulate PI3K, which promotes phosphorylation of Akt through PDK1 or through 
mTORC2. Once activated, Akt regulates FOXOs, GSK3β, Mdm2, and also inhibits 
TSC1/2, which causes the activation of Rheb and mTORC1. mTORC1 regulates mRNA 
translation and ribosome biogenesis via inhibition of 4EBP1 and activation of p70 S6 K. 
Genes designated in green have been demonstrated to harbor gain of function mutations 
or be upregulated in T-ALL. Genes in orange are commonly deleted in T-ALL. (Figure 
adapted from Sabatini et al. Nature Reviews Cancer 2006). 
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CHAPTER II 
 
 
 
 
Differential Regulation of LEF1 in Murine 
and Human T-ALL cell lines 
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Figure Contribution: 
Kathleen Cullion performed experiments in Figures 4A-D, Figure 6 A,B, Figure 7 A-E.  
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Introduction 
 Activating mutations in the NOTCH1 receptor have been detected in greater than 
50% of T-ALL patients and are often found as secondary mutations in murine models of 
the disease 224,228-230. Recent studies have highlighted the requirement of the Notch 
signaling pathway in T-ALL by using γ-secretase inhibitors (GSIs) to interfere with 
Notch signaling 224,230,233,311. In mouse models of T-ALL and in human T-ALL cell lines 
treatment with gamma secretase inhibitors results in G1 arrest and/or apoptosis that can 
be rescued via retroviral expression of intracellular Notch1 (ICN1) 224,230,233,311. In both 
human and mouse T-ALL cell lines, Notch1 driven leukemogenesis is mediated at least 
in part through direct transcriptional regulation of c-MYC 59,163,238. While certainly a 
critical target, in vitro studies indicate that, unlike ICN1, c-MYC in unable to rescue the 
effects of Notch withdrawal in all murine and human T-ALL cell lines, suggesting that 
other as yet unknown Notch1-regulated genes contribute to leukemogenesis 59,163,312.  
 To identify genes dependent on Notch1 signaling we developed a mouse T-ALL 
cell line that expresses a doxycycline-regulated form of ICN1 59. To identify the Notch1 
transcriptional signature in mouse T-ALL we performed gene expression profiling of 
these cells in the presence and absence of doxycycline. c-Myc, Lymphoid enhancing 
factor 1 (Lef1), Early growth response factor 1 (Egr1) as well as known Notch1 targets; 
Hes1, Deltex1, Notch3, Nrarp, Ifi202b, were identified in this initial screen 59.  
 Lef1, a member of the WNT/β catenin pathway, was an attractive target because 
several reports suggest that the Notch1 and WNT pathways may be coordinately 
regulated in development and potentially misregulated in cancer 210,313-320.  Here we 
  
 
40 
validate that Lef1 is a direct Notch1 target in our Tal1 mouse T-ALL mode1. Importantly, 
we demonstrate that while Lef1 is Notch1 regulated in murine T-ALL cell lines, LEF1 
does not appear Notch1 regulated in human T-ALL cell lines. Moreover, positioning of 
CSL sites is not conserved among the mouse and human LEF1 genes and unlike 
intracellular Notch1 and c-Myc, retroviral driven expression of Lef1 fails to rescue T-
ALL cell lines from the effects of Notch inhibition. 
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Results 
Lef1 is a Notch1 dependent gene in murine T-ALL. 
 To identify Notch1-regulated genes in T-ALL, a microarray analysis was 
performed using a leukemic cell line expressing a doxycycline-regulatable intracellular 
Notch1 (ICN1) construct 59, in which the addition of doxycycline inhibits the expression 
of ICN1. Lef1 mRNA levels changed 3.5 fold in the initial microarray screen. To validate 
the array finding, Lef1 expression was evaluated in several mouse T-ALL cells by 
quantitative PCR. The doxycycline-regulatable ICN1 cell line, 3404, was treated with 
2µg/ml of doxycycline in vitro. Decreases in Lef1 mRNA and protein levels were 
observed in the doxycycline treated cells compared to control (Figure 4A,B). Multiple 
mouse leukemic cell lines with detectable Notch1 mutations generated from Tal1 murine 
T-ALL model were then analyzed. These lines were treated with 1µM DAPT for 48 
hours and Lef1 mRNA and protein levels were examined. We observed decreases in both 
Lef1 mRNA and protein expression in all GSI-treated mouse leukemic cell lines 
examined (Figure 4C,D). These data suggest that in mouse T-ALL cell lines, Lef1 
expression is Notch1-dependent.  
 
Lef1 is a direct Notch1 target in murine T-ALL. 
 The decrease in Lef1 mRNA expression in response to GSI or doxycycline 
treatment suggests that Lef1, like c-Myc, may be a gene transcriptionally regulated by 
Notch1. Consistent with this idea, two consensus CSL binding sites, TGGGAA, are 
present in the murine Lef1 promoter approximately 130 and 1200 base pairs upstream of 
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the transcriptional start site (Figure 5A). To determine if Notch1 directly regulates Lef1 
expression, we performed a chromatin immunoprecipitation assay using the doxycycline-
regulated ICN1 leukemic cell line 59. Using this system, we previously demonstrated a 
doxycycline-dependent recruitment of intracellular Notch1 to the promoters of known 
Notch1 targets Hes1 and c-Myc 59. Similarly, we observe a doxycycline-dependent 
recruitment intracellular Notch1 and its coactivator, Mastermind-like 1 (MAML) to the 
murine Lef1 promoter at the -130-135 site (Figure 5B).  Consistent with direct 
transcriptional activation of the locus, ChIP analysis revealed the recruitment of RNA 
polymerase II, Cyclin dependent kinase 9 (CDK9) as well as increases in H3 and H4 
acetylation at the murine Lef1 promoter in Notch1 active leukemic cells (Figure 5B). 
Upon the addition of doxycycline and the inhibition of intracellular Notch1 expression, 
we observed decreased binding of ICN1, MAML, RNA polymerase II and CDK9. These 
findings indicate that Notch1 regulates Lef1 expression in mouse leukemic cells.  
 
Lef1 expression fails to rescue leukemic cell lines from the effects of Notch 
inhibition.  
 Not all murine T-ALL cell lines can be rescued by retroviral expression of c-Myc 
prior to Notch inhibition, suggesting other Notch1 targets remain to be identified. Lef1 
may provide critical proliferation and/or survival signals by regulating targets such as 
Cyclin D1, c-Myc, Myc binding Protein (Mycbp), and Survivin 250-253. To test this, we 
infected two mouse leukemic cell lines; one previously shown to be rescued by c-Myc 
(720) and one unable to be rescued by exogenous-Myc (5046) with the MSCV retrovirus, 
  
 
43 
or a retrovirus expressing intracellular Notch1 (ICN1), or Lef1, or c-Myc. Following 5 
days of GSI treatment, we observed a reduction in the number of viable, GFP+, MSCV-
or Lef1- infected cells, compared to those infected with ICN1 (Figure 6A,B). As 
expected, retroviral expression of ICN1 or c-Myc prevented GSI-induced cell death in 
cell line 720 (Figure 6A). While expression of ICN1 protected 5046-cells from GSI-
induced cell death, expression of neither c-Myc nor Lef1 was capable of rescuing this cell 
line from the effects of Notch1 inhibition (Figure 6B). These results suggest Lef1 
expression alone is not sufficient to mediate leukemic growth by Notch1.  
 
LEF1 does not appear NOTCH1 regulated in human T-ALL cell lines or primary T-
ALL samples. 
 While our group and others have shown Lef1 is a direct Notch1 target in murine 
T-ALL cell lines 321, whether LEF1 is NOTCH1 regulated in human T-ALL cell lines and 
hence a relevant therapeutic target gene remained an unanswered question. To determine 
if NOTCH1 regulates LEF1 expression in human T-ALL cell lines we treated human T-
ALL cell lines, DND-41 and KOPT-K1, with 1µM Compound E or DMSO and examined 
LEF1 expression using quantitative PCR. Both cell lines have NOTCH1 mutations, 
express TAL1, and have previously been demonstrated to be GSI sensitive 233. Unlike c-
MYC, there was little change in LEF1 expression following 4 or 7 days of GSI treatment 
in either DND-41 or KOPT-K1 (Figure 7A,B). These data suggest that at least in these 
two human T-ALL cell lines, LEF1 does not appear NOTCH1 responsive. To rule out the 
possibility that LEF1 may no longer be NOTCH1 regulated in human T-ALL cell lines, 
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we extended our studies to primary T-ALL samples. We identified two patients, 05-386 
and 202-67-64, which express TAL1 and have detectable intracellular NOTCH1 protein 
expression (Figure 7C). These patient cells were treated in vitro with GSI for 48 hours 
and LEF1 and c-MYC gene expression was examined. In contrast to c-MYC, we found 
LEF1 expression unaffected by GSI treatment (Figure 7D,E).  
  
 
45 
Discussion 
 When expressed by a retrovirus, c-Myc is unable to rescue some human and 
murine leukemic cell lines from the effects of Notch inhibition 59,163,312, which suggests 
that other novel Notch1 target genes may contribute to leukemogenesis. Using a murine 
cell line in which transcription of intracellular Notch1 is doxycycline inducible 59, Lef1 
was identified as Notch1 responsive. Further examination revealed Lef1 to be aberrantly 
expressed in cell lines derived from primary Tal1 murine tumors. Using chromatin 
immunoprecipitation we also demonstrated doxycycline-dependent recruitment of 
intracellular Notch1 and co-factor, Mastermind-like 1, to the murine Lef1 promoter. 
These data suggest not only is Lef1 Notch1 regulated in murine T-ALL, but also is a 
direct Notch1 target gene. Since this study, Lef1 was also identified as a direct 
transcriptional target of Notch1 in a E2A-/- model of T-ALL 321. These complimentary 
studies strengthen the finding that Notch1 directly regulates Lef1 in murine 
leukemogenesis. 
 To assess whether Lef1 signaling is sufficient to maintain leukemic growth in the 
absence of Notch1 signaling, murine T-ALL cell lines were infected with Lef1 and 
subsequently treated with a GSI. However, retroviral expression of Lef1 in murine 
leukemic cell lines failed to rescue from GSI induced apoptosis. Although not sufficient 
to sustain leukemic growth, a recent study finds a decrease in the proportion of cells in 
the S phase of the cell cycle upon reduction of Lef1 mRNA expression 321. These data 
suggest that although not sufficient, Lef1 expression is essential for leukemic expansion. 
Lef1 contributes to thymocyte expansion during early thymocyte development 322, 
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however, Lef1 expression is not Notch1 dependent in normal T-cell progenitors 321. The 
reason for direct regulation of Lef1 in murine leukemia and not in normal thymocytes is 
unknown, but could be due to increased intracellular Notch1 expression in leukemic cells. 
This possibility would suggest that the association of Notch1 to the Lef1 promoter is of 
low affinity and only occurs when there are excessive levels of intracellular Notch1.  
 Surprisingly, LEF1 expression does not appear positively regulated by NOTCH1 
in the human T-ALL cell lines or human primary samples tested. The reason for the 
differential regulation of LEF1 in murine versus human T-ALL cell lines is unclear and 
unexpected. Examination of the human LEF1 promoter revealed two potential CSL 
binding sites at positions -500 and -680. However, the site proximal to the transcriptional 
start site is not a conserved CSL consensus site (TGGGGA compared to TGGGAA) (data 
not shown). Perhaps this subtle alteration in the consensus site reduces CSL binding 
affinity to the human LEF1 promoter. The true consensus site in the human LEF1 
promoter is located -680 basepairs upstream of the transcriptional start site. The 
sequences flanking this site do not maintain sequence homology to either of the sites 
found in the mouse promoter. Therefore, it remains possible that transcriptional 
regulation of LEF1 by NOTCH1 is not achieved in human T-ALL because of an inability 
to recruit essential coactivators to this site.  
 These data do not rule out the importance of LEF1 in human T-ALL 
pathogenesis, but does imply that in human T-ALL, LEF1 cannot be the molecular link, 
if any, between Notch1 and WNT signaling. Interestingly, increased expression of TCF1 
is also reported in T-cell malignancies 323, but whether TCF1 contains conserved CSL 
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binding sites and is a direct NOTCH1 target has not been tested. It is also possible that in 
human T-ALL, another direct NOTCH1 target contributes to Notch1/WNT cross talk. 
For example, in endothelial cells, Nrarp acts as a molecular link between Notch and 
WNT signaling 319, however, whether NRARP is misexpressed in human T-ALL and 
retains these functions in this model system remains unknown.  
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Materials and Methods 
Mouse and Human T-ALL Cell Lines  
Murine leukemic cell lines were cultured in RPMI with 10% FBS, 1% glutamine, 
Penicillin/ Streptomycin, 50µM β mercaptoethanol at 37 C under 5% CO2.  Human T-
ALL cell lines and primary human leukemic cells were cultured in RPMI with 10% FBS, 
1% glutamine, Penicillin/ Streptomycin at 37 C under 5% CO2. To inhibit Notch1 
signaling, cells were plated at 1x106 in a 10cm dish in the presence of either MRK-003 
(Merck Research Laboratories, Boston, MA) at 1µM or compound E (Axxora, San 
Diego, CA) at 1µM. Mock treated cells were cultured with DMSO at a final 
concentration of 0.01%.  
Western Blot Analysis 
Murine leukemic cells lines were lysed in 20mM Tris buffer pH  7.4 containing 0.14 M 
NaCl, 1% NP-40, 10% glycerol, 1mM sodium orthovanadate and protease inhibitors and 
protein concentrations determined using the Bradford assay (Bio-Rad, Hercules, CA). 
Protein was resolved on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane. 
The following antibodies were used for immunoblotting: ICN Val1744 (#2421 Cell 
Signaling Technology, Beverly, MA) and Lef1 antibodies (Clone 2D12 Upstate, Lake 
Placid, NY). Blots were stripped and reprobed with β-Actin (#A5441, Sigma, St. Louis, 
MO) to ensure equal loading.  
RNA Analysis 
RNA was extracted from murine T-ALL cell lines using Trizol. cDNA was synthesized 
using Superscript First - Strand Synthesis System (Invitrogen, Carlsbad, CA). Primers 
  
 
49 
were designed using Primer Express software (Applied Biosystems, Foster City, CA). 
The primer sequences are as follows; murine Lef1 forward, 5'-
TCCTCTCAGGAGCCCTACCA-3’; murine Lef1 reverse, 5'-
GGCCTCCGTCTGGATGCT-3’; human LEF1 forward, 5’-
TACCACGACAAGGCCAGAGAA-3’; human LEF1 reverse, 5’-
TGGCATCATTATGTACCCGGA-3’. Human C-MYC expression was measured using: 
human C-MYC forward, 5’-GCAGCTGCTTAGACGCTGGATTTT-3’; human C-MYC 
reverse, 5’-GCAGCAGCTCGAATTTCTTCCAGA-3’.  The copy number obtained for 
the gene of interest was normalized to the copy number for ß-Actin, using primers 
previously described 59. Relative quantities of mRNA expression were analyzed using 
QRT-PCR in the presence of SYBR green (Applied Biosystems ABI prism 7300 
Sequence Detection System, Applied Biosystems, Foster City, CA). 
ChIP Assay 
Chromatin immunoprecipitation was performed as described previously 59. The following 
primer set was used to amplify the region of the murine Lef1 promoter forward: 
GAAGCGACGCAAGTGAATAGCTT; murine Lef1 promoter reverse: 
AATGTCCGAATGCCAGGGCCCACGA.  
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Figure 4. Notch1 regulates mouse Lef1 expression. (A) Expression of Lef1 was 
examined by quantitative PCR following 48 hours of treatment with doxycycline or 
DMSO control using the doxycycline-regulated ICN1 T-ALL cell line, 3404. β-Actin 
was used an internal control. (B) Cells left untreated or treated with 2µg/ml doxycycline 
for the time periods indicated. Cell lysates were separated by 10% SDS-PAGE gel and 
then probed with anti-Lef1 and anti-β Actin antibodies. (C) Mouse T-ALL cell lines, 720 
and 5046, were treated with DMSO or 1µM GSI (DAPT) for 48 hours and Lef1 
expression was examined using quantitative PCR. (D) Cell lysates were separated by 
10% SDS-PAGE gel and then probed with anti-Lef1 and anti- β Actin antibodies. 
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Figure 5. Dox-dependent recruitment of ICN1 and Mastermind-like 1 (MAML) to 
the Lef1 promoter. (A) Schematic representation of the murine Lef1 promoter. 
Canonical CSL binding sites and their positions relative to the transcriptional start site are 
highlighted. (B) Chromatin immunoprecipitation assay (ChIP) for CSL, Notch1, MAML, 
RNA polymerase II, and CDK9 at the murine -130-135 site. The dox-dependent 3404 
leukemic line was treated with doxycycline (2µg/ml) for 48 hours or left untreated. 
Immunoprecipitations (IPs) were carried out using respective monoclonal or polyclonal 
antibodies or without antibody (No-Ab) as control. Immunoprecipitated and input DNA 
were amplified by PCR using primers specific for the Lef1 promoter. PCR amplified 
products were analyzed on a 2% agarose gel. 
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Figure 6. Lef1 does not rescue leukemic cells from the withdrawal of Notch 
signaling.  Two murine leukemic cell lines, 720 (A) and 5046 (B) were left uninfected or 
were infected with MSCV retroviral vectors expressing Lef1, c-Myc or ICN. GFP+ cells 
were then treated with DMSO or with 1µM GSI (DAPT) for 6 days, and viability was 
determined by trypan blue staining. 
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Figure 7. LEF1 does not appear NOTCH1 regulated in human T-ALL cell lines or 
primary samples tested. Human leukemic cell lines DND-41 (A) and KOPT-K1 (B) 
were left untreated or were treated with Compound E (1µM) for the time points indicated. 
LEF1 and c-MYC expression was examined by quantitative PCR. β-Actin was used an 
internal control. Primary patient samples were examined for intracellular Notch1 and 
human TAL1 expression by immunoblotting with intracellular Notch1 (anti-NotchIC 
Val11744) and human TAL1 antibodies (C). Cells from patient 05-386 (D) and 202-67-
64 (E) were left untreated or were treated with Compound E (1µM) for 48 hours. LEF1 
and c-MYC expression was examined by quantitative PCR. β-Actin was used an internal 
control. 
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Chapter III 
 
 
 
 
 
 
Targeting the Notch1 and mTOR pathways  
in a Mouse T-ALL Model 
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Data presented in this chapter has been published as: 
 
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model 
 
Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, 
Krishnamoorthy V, Majumder PK, Kelliher MA. 
Blood. 2009 Jun 11;113(24):6172-81.   
PMID: 19246562  
 
Figure Contribution: 
Kathleen Cullion provided the data in Figure 8B, 9B, 10, as well as Figures 12- 16 and 
Table 2.  
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Introduction 
 Treatment of mouse Tal1 leukemic cell lines in vitro with γ-secretase inhibitors 
(GSIs) results in cell cycle arrest and apoptosis, revealing that Notch1 signaling is 
required for leukemic growth/survival 230.  Although the majority of mouse Tal1 
leukemic cell lines undergo apoptosis upon GSI treatment in vitro, it remains to be tested 
whether Notch1 can be inhibited for extended periods of time in vivo.  An additional 
concern regarding targeting the Notch pathway in T-ALL is that in contrast to mouse, 
many human T-ALL lines appear relatively GSI resistant in vitro 224,232,238, raising the 
possibility that GSIs alone may not prove effective in the treatment of T-ALL patients.  
Moreover, whether GSIs can be administered in vivo for extended periods of time at 
lower doses without associated toxicities remains uncertain.   
 In this study, we examined the effects of GSI treatment in our mouse T-ALL 
model.  To examine GSI efficacy, we treated near end stage leukemic mice and found 
that GSI treatment extends the survival of leukemic mice, but is not sufficient to 
eliminate disease. In addition, we find that mouse Tal1 leukemic cell lines isolated from 
GSI treated mice exhibit mTOR pathway activation, suggesting that mTOR inhibitors 
may synergize with GSI to limit leukemic growth/survival.  Treatment of mouse T-ALL 
cell lines with GSI or rapamycin reduces mTOR activity, however combined GSI and 
rapamycin treatment further ablates mTOR kinase activity, resulting in increased 
apoptosis. GSI and rapamycin treatment reduced human leukemic growth in vivo and 
significantly increased overall survival.  Collectively, this work supports the idea of 
targeting NOTCH1 in the treatment of T-ALL.  
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 Results 
MRK-003 represses Notch1 target gene expression and induces apoptosis of mouse 
T-ALL cell lines and primary Tal1/Ink4a/Arf+/- tumors. 
 The prevalence of mutations that result in activated NOTCH1 in patients with T-
ALL raises the possibility that GSIs used to inhibit Notch1 and other GS-dependent 
substrates in vitro may have anti-leukemic activity in the clinic. To evaluate the ability of 
the GSI, MRK-003, to inhibit Notch1, multiple mouse T-ALL cell lines were treated with 
1µM or 10µM of MRK-003 and Notch1 target gene expression examined. Decreased 
levels of Hes1 and Deltex1 expression were observed in the MRK-003 treated cultures 
following treatment for 24 hours (Figure 8A).  We then compared the relative 
effectiveness of MRK-003 with N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine 
t-butyl ester (DAPT), another GSI known to inhibit mouse leukemic growth 230.  Multiple 
mouse T-ALL cell lines were treated with 1µM MRK-003 or with 1µΜ DAPT for three 
days and cell cycle analysis performed.  In all three of the cell lines tested, increases in 
the percentage of apoptotic cells were observed in MRK-003 treated cultures compared to 
treatment with either DMSO (vehicle) or DAPT (Figure 8B).  These in vitro data suggest 
that MRK-003 may be effective at inhibiting Notch1-mediated leukemic growth in vivo. 
To test this, thymic tumor explants (masses) isolated directly from Tal1/Ink4a/Arf +/- 
mice were treated with DMSO (vehicle) only, with 1µM DAPT or 1 µΜ MRK-003 for 
three days. The percentage of apoptotic cells was then determined by Annexin V/PI 
staining followed by flow cytometry. We found MRK-003 treated cultures contained 
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significantly more apoptotic cells than were observed in either the DMSO or DAPT 
treated cultures (Figure 8C; p=0.0273 by Kruskal-Wallis test 324). 
 
GSI treatment prolongs survival in a mouse T-ALL model. 
 These ex vivo studies indicated that MRK-003 administration to leukemic mice 
might induce apoptosis in vivo, decrease tumor burden, and increase overall survival.  To 
test this possibility, we treated mice daily with 50mg/kg, 200mg/kg or 1000 mg/kg of 
MRK-003 and determined plasma concentrations of the compound.  We found that 
effective plasma MRK-003 concentrations (1-10µM) were achieved in mice treated with 
all three doses (Figure 9A).  However, when the MRK-003 compound was given daily at 
150mg/kg, the mice began to develop diarrhea and lose weight (Figure 9C: R1 compared 
to V1). Chronic GSI administration is known to result in gastrointestinal (GI) toxicity due 
to Notch inhibition in the intestinal epithelium, resulting in gut metaplasia 201,203,310,325. To 
assess GSI efficacy on mouse leukemic growth, we adopted an intermittent GSI dosing 
regimen that achieved effective concentrations of the drug without associated toxicities.  
Specifically, mice treated with 150mg/kg MRK-003 for three days followed by a four day 
rest period, had effective plasma compound levels (Figure 9B), did not exhibit evidence 
of body weight loss (Figure 9C: R2 compared to V1), and exhibited limited gut 
metaplasia (Figure 10). MRK-003 plasma levels peak following administration and 
effective drug concentrations are detected at 24 hours post treatment. Between 3-4 days 
post MRK-003 administration, compound levels decrease to below detectable levels and 
by 96 hours, decreases in goblet cells can be observed in the colons of the treated mice 
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(Figure 10). These data indicate that the gut epithelium recovers during the 4 day “off” 
period. GSI plasma concentrations were also measured each week following three full 
cycles of the intermittent dosing regimen to determine if the compound accumulates upon 
successive treatment. We found no significant change in plasma concentration following 
three cycles of intermittent dosing (data not shown). Additionally, in a pre-clinical mouse 
model, this intermittent dosing schedule was well tolerated, as no evidence of intestinal 
effects were detected following a 35 day treatment period (Tammam et al. Manuscript in 
preparation). 
 In an attempt to accurately reflect the clinical experience, near end stage leukemic 
Tal1/Ink4a/Arf+/- mice were treated with either vehicle or 150mg/kg MRK-003 for three 
days followed by a four day recovery period.  Following the three days of GSI treatment, 
plasma compound levels were determined and an EC50 of 5-10µM of MRK-003 was 
achieved. Leukemic mice were treated with vehicle or MRK-003 following the three days 
on, four days off treatment regimen throughout the duration of the study. We found that 
GSI treatment resulted in a statistically significant increase in overall survival of 
leukemic mice when compared to vehicle treated mice (Figure 9D; p< 0.005). The 
median survival period for GSI treated mice was 18 days compared to 3 days for the 
vehicle treated group. In most cases, responses were evident in the MRK-003 treated 
mice immediately following the three day treatment period, as measured by an increase in 
physical activity and improved rates of respiration. Importantly, body weights are 
maintained in MRK-003 treated animals following successive cycles of intermittent GSI 
dosing (Table 1). This pilot study supports the idea that GSI-associated toxicities may be 
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overcome with intermittent dosing and provides evidence that Notch1 inhibition 
improves mouse leukemic survival in vivo.   
 
GSI treatment induces apoptosis of leukemic cells in vivo. 
 To determine whether GSI treatment induced apoptosis in vivo, we performed 
TUNEL staining on thymomas isolated from vehicle or GSI treated mice.  We detected 
increases in the percentage of apoptotic tumor cells in mice treated with MRK-003, 
compared to tumors exposed to vehicle only (Figure 11A and B; p=0.0339 by Wilcoxon's 
rank sum test 324).  However, similar to our in vitro data (Figure 8B), the in vivo response 
to GSI was variable.  Three of the four GSI treated mice examined exhibited an increase 
in apoptosis of leukemic cells, ranging from 2-10-fold increases in TUNEL positive 
tumor cells (Figure 11B).  An increase in TUNEL positive cells was not observed in one 
of four tumors from the GSI treated group (mouse 6448). However, we were unable to 
detect a Notch1 mutation in this tumor. The reasons for the variable GSI responses both 
in vitro and in vivo are unclear. One possibility for the variable in vivo responses may be 
that some tumors require longer treatment periods. For these studies, leukemic mice were 
treated with vehicle or with GSI for 3 days and then the mice were sacrificed and tumor 
sections analyzed for the presence of apoptotic cells. It is conceivable that more 
consistent responses may be observed in leukemic mice treated with multiple GSI doses. 
Nonetheless, GSI treatment clearly induced apoptosis and extended the survival of 
leukemic mice. 
 
  
 
61 
Transient GSI responses do not reflect development of GSI resistance. 
 Another potential reason for variable responses may be that the GSI treated mice 
develop GSI resistance. To exclude this possibility, T-ALL cell lines were generated 
from the GSI and vehicle treated mice and their response to GSI quantified in vitro. As 
expected, truncated Notch1 proteins were detected in the vehicle treated tumor 6856 and 
the GSI treated tumors 6838 and 6904. In contrast, a full length Notch1 protein appears 
expressed in tumor 6837, although increased intracellular Notch1 protein levels are 
observed, suggesting that this tumor may harbor mutations in other regulators of Notch1 
protein stability. In all tumors, GSI treatment in vitro significantly reduced Notch1 
protein levels, as assessed by immunoblotting with the anti-Notch1 V1744 antibody, 
which is specific for cleaved Notch1 (Figure 12A). Leukemic cell lines also clearly 
remained dependent on Notch1 for growth, as G1 arrest and apoptosis was observed upon 
GSI treatment (Figure 12B). These findings indicate that transient responses to GSI in 
vivo do not reflect the development of GSI resistance. 
 
Repression of Notch1 target gene expression in GSI treated mice.  
 To further understand why GSI treatment prolonged survival but failed to 
eliminate disease, we examined Notch1 target gene expression (Deltex1, c-Myc, Hes1 and 
Pre-Tα) in the vehicle and GSI treated leukemic cohorts using real time PCR (Figure 
13A-D). We found c-Myc and Deltex1 expression was reduced in MRK-003 treated 
leukemic mice compared to mice treated with vehicle only (Figure 13A,C). The 
difference in c-Myc and Deltex1 expression in the GSI versus vehicle treated leukemic 
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mice was statistically significant (p=0.015 and p=0.027, respectively by Wilcoxon's rank 
sum test 324). Moreover, the c-Myc and Deltex1 mRNA levels observed in vivo 
approximate expression levels observed when the mouse T-ALL cell line 720 was treated 
with GSI in vitro. In contrast, differences in Hes1 and Pre-Tα expression did not reach 
statistical significance (Figure 13B,D), suggesting that these genes may also be regulated 
by other transcription factors in mouse T-ALL cells. This study also raises the possibility 
that C-MYC and/or DELTEX1 expression levels may serve as reliable biomarkers of 
NOTCH1 activity in T-ALL patients. 
 
mTOR pathway is active in mouse T-ALL tumors and cell lines. 
 Published work by Chan et al reveal mTOR activation in human T-ALL cell lines 
and their in vitro studies suggest that GSI and the mTOR inhibitor rapamycin may act 
synergistically to arrest human leukemic growth in vitro 326. To assess mTOR activity in 
murine T-ALL, we examined primary mouse T-ALL tumor cells and murine T-ALL cell 
lines for evidence of Akt/mTOR activation. By staining thymomas with antibodies 
specific to phospho-Akt and phospho-S6 ribosomal protein, we identified a subset of 
primary murine T-ALL tumor cells as Akt/mTOR active (Figure 14A). Similarly, 
staining of primary murine T-ALL tumor cells prior to conversion to culture revealed 
evidence of mTOR activation, as measured by staining phospho-S6 ribosomal protein, 
intracellularly (Figure 14B). Phosphorylation of S6 ribosomal protein is reduced upon 
rapamycin treatment, suggesting activation is mTOR dependent.  
 In addition, all of the mouse T-ALL cell lines we examined exhibited mTOR 
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activation as assayed by phospho-p70 S6 kinase and phospho-S6 ribosomal levels (Table 
2, n=10). Activation of the Akt pathway, as assayed by phospho-Akt, was not observed in 
all of the cell lines examined. Cell lines in which phospho-Akt was not detected, did have 
increased expression of Pten. Expression of Pten and suppression of the Akt pathway was 
not correlated with Notch1 mutational status or GSI sensitivity as suggested by recent 
studies (Table 2, n=10) 327. Irrespective of the Pten status, all mouse leukemic lines 
exhibited increased amounts of phosphorylated mTOR substrates, which suggest at least 
in Pten-positive cell lines, the activation of the mTOR pathway is occurring in an Akt 
independent manner.  
 
GSI treatment reduces mTOR pathway activity 
 To asses whether active Notch signaling contributes to mTOR activation in 
murine T-ALL, three mouse T-ALL lines (720, 5046 and 5151) were treated with GSIs 
and mTOR pathway activation was assayed by measuring phospho-p70 S6 kinase and 
phospho-S6 ribosomal protein levels. In each of the three lines, GSI treatment resulted in 
reduced phospho-p70 S6 kinase and phospho-S6 ribosomal protein levels (Figure 15A). 
However, GSI treatment was not sufficient to abolish mTOR activity in any of the mouse 
T-ALL cell lines examined. Notch1 has been thought to mediate thymocyte survival by 
direct activation of Akt 118,  and based on these findings we examined the phosphorylation 
of Akt using an anti-phospho-Akt Ser 473 antibody. In mouse leukemic cells where Pten 
is not expressed, GSI treatment reduced the phosphorylation of Akt (Figure 15B), 
however, Akt phosphorylation could not be measured in leukemic cell lines where Pten 
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was expressed. Collectively, these data indicate that at least in Pten-negative mouse 
leukemic cells, Notch1 signaling stimulates Akt activity. Additionally, GSI treatment 
reduces but does not eliminate mTOR activity, indicating that GSIs and the mTOR 
inhibitor rapamycin may be required to completely inactivate mTOR in leukemic cells.  
 
GSI and rapamycin treatment ablates mTOR kinase activity and induces apoptosis. 
 These signaling data suggested that rapamycin treatment may inhibit leukemic 
growth and that GSI and rapamycin treatment may prove more effective at inducing 
leukemic cell death.  We tested this possibility by treating our mouse leukemic cell lines 
with vehicle, 1µM MRK-003, 10nM rapamycin or with 1µM MRK-003 and 10 nM 
rapamycin and quantified the apoptotic leukemic cells by PI staining followed by flow 
cytometry.  In all cases, treatment with GSI and rapamycin induced more cell death than 
treatment with GSI or rapamycin alone (Figure 16A).  At the concentrations tested, the 
effects of MRK-003 and rapamycin treatment on leukemic apoptosis appeared at a 
minimum, additive.  
 To obtain a molecular readout of the combination treatment, we measured mTOR 
targets; phospho-p70 and p-85 S6 kinase levels in leukemic cell lines treated with 
vehicle, GSI or rapamycin alone or with both GSI and rapamycin.  We found that 
treatment with either GSI or rapamycin reduced phospho-p70 S6 kinase activity, but 
treatment with either single agent failed to ablate mTOR activation (Figure 16B).  In 
contrast, p70 S6 kinase activity and the hyperphosphorylated p85 S6 kinase were 
undetectable when leukemic cell lines were treated with both GSI and rapamycin (Figure 
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16B). These findings indicate that the suppression of the mTOR and Notch1 pathways 
result in extensive apoptosis of mouse leukemic cells, thereby supporting the idea that 
GSI and rapamycin may be efficacious in the clinic.  
 Moreover, our in vitro studies and work done by Chan et al 326 support the idea 
that MRK-003 and rapamycin may have synergistic effects on mouse leukemic growth. 
To test this possibility, mouse leukemic cells were cultured with 1nM rapamycin and 
increasing concentrations of MRK-003 (10-5 – 101 µM) for 72 hours and leukemic growth 
was assayed using MTT assay. Treatment with 1nM of rapamycin resulted in modest 
growth inhibition and as expected, MRK-003 caused extensive cell death between the 1 
and 10µM concentrations (Figure 16C).  Treatment of both drugs, specifically at low 
pharmacologic doses, appeared to have synergistic effects, resulting in a greater than 
additive amount of growth inhibition detected.  These results support the idea that 
reduced concentration of GSIs may be used when administered in combination with 
rapamycin to increase the therapeutic window.  
 
GSI and rapamycin treatment inhibits human T-ALL growth and prolongs 
survival. 
 One potential limitation of these studies is that mouse leukemic cell lines appear 
more sensitive to GSI treatment than established human T-ALL cell lines 224,232,233,238. 
GSI treatment of mouse leukemic cell lines induces apoptosis by 48-72 hours (Figure 
16A and Figure 8B), whereas human T-ALL cell lines require six or more days of GSI 
treatment to induce, at best, a modest G1 arrest. The reasons for the differential response 
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to GSI remain unclear and may reflect activation of additional anti-apoptotic pathways in 
the human T-ALL. Alternatively, mouse leukemic cell line sensitivity to GSIs may reflect 
inherent differences between the species. To test the effects of GSI and rapamycin 
treatment on human leukemic growth and survival, human T-ALL cell lines were treated 
in vitro with increasing concentrations of MRK-003 in the presence of 1nM or 100nM 
rapamycin and ATP activity was measured using a Vialight assay kit. As expected, 
increasing amounts of GSI reduced human leukemic growth, however the addition of 
rapamycin enhanced the effects of GSI treatment, resulting in greater inhibition of growth 
(Figure 17A). Thus, reduced concentrations of GSI may be used in vivo in combination 
with rapamycin to minimize on target GSI-associated toxicities and to maximize efficacy. 
 We then tested whether GSI and rapamycin in combination could have additional 
efficacy against human leukemic growth in vivo.  To perform this study, approximately 5 
x106 human T-ALL cells from the cell line T-ALL1 were implanted subcutaneously into 
nude mice and once the tumors reached 200mm3, mice were randomized into four 
treatment groups of eight mice each.  Mice were then treated with vehicle, a non-
efficacious dose of GSI (MRK-003 150mg/kg/once per week), rapamycin (Rapamune 
20mg/kg daily) or GSI and rapamycin and time to disease progression determined. Mice 
treated with GSI or rapamycin exhibited inhibition of tumor progression, as measured by 
percent test normalized to control tumor volume (Figure 17B), however, overall survival 
was not affected (Figure 17C).  In contrast, mice treated with GSI and rapamycin 
survived on average longer than vehicle treated mice or mice treated with either single 
agent (GSI or rapamycin alone) (Figure 17C).  The administration of GSI and rapamycin 
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resulted in an increase in the percentage of mice surviving (60 versus 25%) as well as an 
increase in the mean survival period of more than 50 days (p<0.058 by logrank test).  
Mice treated with either GSI or rapamycin succumbed to disease rapidly with an average 
latency of approximately 40 days.  Collectively, these in vivo studies suggest that GSI in 
combination with the mTOR inhibitor rapamycin may have added efficacy in the 
treatment of T-ALL patients that exhibit NOTCH1 activation. 
  
 
68 
Discussion 
 The prevalence of NOTCH1 and FBXW7 219-224 mutations in human T-ALL and 
in mouse T-ALL models 228-231 prompted several laboratories to ask whether leukemic 
growth remained NOTCH1-dependent.  GSI treatment of mouse and human T-ALL cell 
lines and primary mouse tumors expressing mutated Notch1 proteins revealed that 
sustained Notch1 signals appear required for continued growth and survival in vitro 
224,230,232,233,238. These findings raise the exciting possibility that Notch1 inhibition may 
prove effective in treating T-ALL patients and led to the opening of a phase 1 clinical 
trial involving 8 relapsed leukemia and lymphoma patients. Most of the patients were 
dosed with a continuous GSI dosing schedule, which was poorly tolerated, and the trial 
closed prior to being able to demonstrate clinical activity of GSIs in T-ALL 309. A well-
tolerated intermittent GSI dosing regimen for patients has since been identified thereby 
facilitating future clinical evaluations of GSIs in T-ALL and potentially other cancers.  
 Here we examined the effect of GSI treatment in our mouse T-ALL model where 
the effects of Notch1 inhibition could be addressed on primary tumors opposed to 
patients with relapsed or refractory disease. Seventy four percent of Tal1/Ink4a/Arf+/- 
transgenic mice develop a T-ALL like disease due to mutations that result in premature 
truncation of the Notch1 receptor 230. To investigate whether Notch1 could be targeted in 
vivo, we developed an intermittent GSI dosing regimen (150mg/kg three days on and four 
days off) that had minimal toxicity and then tested whether this regimen had any effect 
on the survival of leukemic Tal1/Ink4a/Arf+/- mice.  We found that GSI treated mice 
survived on average 15 days longer than leukemic mice treated with vehicle only. The 
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expression of Notch1 target gene expression Deltex1 and c-Myc was repressed and 
increased numbers of apoptotic cells were detected in the thymic masses of diseased mice 
treated with GSI.  These data support the idea that Notch can be successfully targeted in 
vivo and that treatment with GSI as a single agent has efficacy and extended the survival 
of leukemic mice. 
 Despite the expression of other T-ALL associated oncogenes such as Tal1 and 
Lmo1/2 and the loss of tumor suppressors (Ink4a/Arf, Pten), mouse T-cell leukemic 
growth appears preferentially ‘addicted’ to the Notch1 proliferative signal(s).  Although 
GSI treatment significantly increased the overall survival period, it was not sufficient to 
cure the mice and 100% of the GSI treated mice eventually succumbed to disease.  The 
transient GSI response was not due to the development of GSI resistance, as all mouse 
tumors tested remained GSI responsive when re-examined in vitro.  One possibility is 
that the transient response to GSI may reflect the intermittent dosing regimen and long 
term suppression of Notch1 activity may require more frequent GSI administration or 
combination therapies. Alternatively, chronic GSI treatment may promote reliance on 
other growth and survival pathways.  For example, Gleevec administration to mice with 
CML-like disease shifts the reliance from activated ABL towards a greater dependence 
on the IL-7 signaling pathway 328.  
 As in human T-ALL 327, PTEN loss of expression is frequently observed in our 
mouse T-ALL model (Table 2). In human T-ALL cell lines and primary samples, loss of 
PTEN has been associated with resistance to NOTCH1 inhibition 327. Interestingly, 2 of 6 
mouse T-ALL cell lines examined harbor Notch1 mutations and express Pten, whereas 
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the remaining 4 mutant Notch1 mouse T-ALL cell lines do not express Pten. Yet, all 6 
mouse T-ALL cell lines remain GSI responsive, irrespective of their Pten status. Unlike 
the reported role of PTEN in GSI resistance in human T-ALL cell lines 327, we observe 
no correlation between Pten status and GSI responsiveness. However, it is important to 
note that GSI resistant mouse T-ALL cell lines are relatively rare and thus far, we have 
isolated only 2 GSI resistant mouse T-ALL cell lines; one of them retains Pten, whereas 
the other does not. Nonetheless, it is clear in our mouse T-ALL model, Pten loss does not 
result in GSI resistance and these mouse T-ALL cell lines remain dependent on Notch1 
for their growth and survival.  
 Although the results from this mouse GSI study are promising, many human T-
ALL cell lines are far less responsive to GSI treatment in vitro 224,232,233,238. Even at 
increased concentrations and extended incubation periods, only modest amounts of cell 
death are observed when human T-ALL cell lines or primary leukemic samples are 
treated with GSIs. These findings cast doubt as to whether GSI or other Notch1 inhibitors 
will be effective in T-ALL patients. Collectively, these data suggest that combination 
therapies may be needed to successfully treat T-ALL patients. We provide evidence that 
combining GSI treatment with the mTOR inhibitor, rapamycin, limits human leukemic 
growth in vivo and increases the overall survival. Moreover, the combination treatment is 
effective following only one GSI dose, indicating that lower concentrations of GSI may 
prove effective when administered in combination with other anti-leukemic agents. 
Similarly, work by Chan et al show that GSI and rapamycin synergize to limit human T-
ALL cell line growth in vitro 326. We extend their in vitro findings and show that Notch 
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and mTOR pathway inhibition limits human leukemic growth in vivo, when tested in a 
mouse xenograft setting. Thus, whether GSI and rapamycin will prove efficacious 
remains to be tested in mouse T-ALL models.  
 Notch receptors and ligands are found upregulated in multiple human cancers 
(reviewed in 329) and expression of activated Notch alleles results in T-ALL like disease 
122,216,330 and induction of mammary tumors in mice 331. In addition to cell autonomous 
effects, Notch pathway inhibition may also have anti-angiogenic activity 332-335 and 
thereby render a ‘double hit’ to the malignant cell. Thus, Notch inhibitors may have 
enormous potential in targeted cancer therapy. 
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Materials and Methods 
Mouse and Human T-ALL Cell Lines  
Murine T-ALL cell lines were cultured in RPMI with 10% FBS, 1% glutamine, 
penicillin/ streptomycin, 50µM β mercaptoethanol at 37 C under 5% CO2.  Human T-
ALL cell lines were cultured in RPMI with 10% FBS, 1% glutamine, penicillin/ 
streptomycin at 37 C under 5% CO2. To inhibit Notch1 signaling, cells were plated at 
1x106 in a 10cm dish in the presence of either MRK-003 (Merck Research Laboratories, 
Boston, MA) at 1µM, rapamycin at 10nM (LC Laboratories, Woburn, MA), or a 
combination of MRK-003 and rapamycin. Mock treated cells were cultured with DMSO 
at a final concentration of 0.01%. All mouse procedures performed in these experiments 
have been approved by the University of Massachusetts Medical School Institutional 
Animal Care and Use Committee (IACUC). 
GSI efficacy studies  
A cohort of Tal1/Ink4a/Arf +/- transgenic mice was generated (n= 30) and monitored 
daily for the onset of leukemia as described previously 61.  Once disease became evident 
(respiratory distress, decrease in activity, weight loss, ruffled coat) leukemic 
Tal1/Ink4a/Arf +/- mice were randomly assigned to the vehicle or GSI treatment groups 
(vehicle cohort n=14, GSI cohort n=16).   Leukemic mice were administered either a 
150mg/kg dose of freshly prepared MRK-003 (dissolved in 0.5% methylcellulose) or a 
comparable volume of 0.5% methylcellulose by oral gavage.  Mice were treated for three 
consecutive days followed by a rest period of four days.  Mice were continuously treated 
with this regimen throughout the study period and euthanized when deemed moribund by 
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a third party blinded to the treatment group. Survival data was plotted using Kaplan-
Meyer survival curves and statistical analysis performed using SPSS software. To 
examine the effects on human leukemic growth, female CD1 nu/nu mice (Charles River 
Laboratories, Wilmington, MA) were inoculated with human TALL-1 cells (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ) Braunschweig, Germany) 
three days after an intraperitoneal inoculation of 100mg/kg cyclophosphamide (no. 
C0768-1G; Sigma Aldrich, St. Louis, MO) to facilitate tumor growth. TALL-1 cells were 
implanted at a concentration 5x106 cells diluted in 100µl of 50% matrigel (no. CB-
40230C; Fisher Scientific, Pittsburgh, PA)/50% PBS.  When tumors reached 200mm3, 
mice were randomized into groups (n=12) of equal average tumor volume.  MRK-003 
was dosed at either 0 or 150 mg/kg by oral gavage once a week.  Rapamycin (rapamune) 
was administered by oral gavage daily at a concentration of either 0 or 20 mg/kg.  
Tumors were callipered and body weights were recorded twice weekly for the duration of 
study.  Mice were euthanized when tumors reached the maximum volume allowed by 
IACUC guidelines. Survival data was plotted as a Kaplan-Meyer survival curve using 
Prism Graphpad software (GraphPad Software, San Diego, CA).  Repeated measures 
analysis of variance was used for the comparison of tumor growth inhibition. MRK-003 
levels in plasma, and in tumor were measured by High-Pressure Liquid Chromotography 
using Cohesive Technologies pump and auto-sampler (Thermo Scientific, Waltham, MA) 
equipped with a reversed-phase column (Atlanis C18, 3µm, 3 x 20mm; Waters, Milford, 
MA) and linear water/ANC gradient (5-90% organic in 3 minutes) containing 0.1% 
formic acid at a flow rate of 850 µL/min. The protonated molecules were fragmented by 
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collision-induced dissociation with nitrogen as a collision gas. The collision energy 
voltage was set at 35V and 48V for GSI and internal standard respectively. The data were 
acquired and processed by Analyst 1.4.1 software (AB/MDS Sciex, Foster City, CA).  
TUNEL staining 
To quantify apoptotic cells, leukemic mice treated with a 150mg/kg dose of MRK-003 or 
0.5% methylcellulose orally for three days, were euthanized and a post-mortem 
examination was performed. Paraffin embedded tumor sections were analyzed for 
apoptosis using the ApopTag Plus peroxidase TUNEL kit (Chemicon, Temecula, CA). 
Approximately, 10 fields from each slide were counted and compared to the serial section 
not treated with the TdT enzyme. Wilcoxon's rank sum test was used to determine 
statistical significance 324. Images were taken using an Olympus BX41 microscope 
(Olympus Imaging America, Center Valley, PA) with a 20x or 40x lenses. The images 
were acquired with an Evolution MP 5.0 camera (Media Cybernetics, Bethesda, MD) and 
Q capture Pro 5.1 acquisition software. 
Immunohistochemistry 
Paraffin embedded tumor sections were analyzed for phospho-S6 ribosomal protein 
expression (1:75; Cell Signaling Technology, Beverly, MA). Automated staining was 
performed using the ChromoMap Kit on the Discovery XT (Ventana Medical System) 
under standard conditions. Periodic Acid Schiff (PAS) staining of mouse duodenum was 
conducted as previously described 201. Images were taken using a Carl Zeiss 
Imager.Z1 Plan-Apochromat  (Carl Zeiss, Jena, Germany) with a 20X objective lens. The 
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images were acquired using a Carl Zeiss AxioCam HRc camera and the imaging-
acquisition software used was Carl Zeiss AxioVision Rel. 4.6. 
Flow cytometry 
To determine the effects of GSI and/or rapamycin treatment on the cell cycle, mouse and 
human leukemic cells were pelleted by centrifugation for 10 minutes at 2000 rpm, 
washed in PBS, and resuspended in 70% ice-cold ethanol. Cells were fixed overnight and 
then stained with propidium iodide. DNA content was analyzed by flow cytometry 
(FACScan; BD Biosciences, San Jose, CA). Data was analyzed using FlowJo version 7.0 
(TreeStar, Ashland, OR). To quantify the effects of GSI on primary tumors, thymic 
masses isolated directly from Tal1 transgenic animals were treated ex vivo with GSI or 
vehicle and then were stained with FITC-Annexin V/PI and analyzed by flow cytometry 
(BD Biosciences, San Jose, CA).  
For intracellular-S6-Ribosomal staining, cells from bone marrow or spleens of leukemic 
animals were fixed directly with 1.5% paraformaldehyde for 10 minutes at room 
temperature. Cells were pelleted by centrifugation at 500g for 5 minutes and incubated in 
100% ice cold methanol at 4°C for 10 minutes to 16 hrs. Cells were washed twice with 
intracellular staining buffer (PBS, 0.5% BSA, 0.02% sodium aside) and then incubated 
with antibodies for 30 minutes at room temperature. Cells were then washed with 
Intracellular staining buffer and measured by flow cytometry.  Data was analyzed using 
FlowJo software (Tree Star Inc., Ashland, OR).  
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RNA Analysis 
RNA was extracted from murine T-ALL cell lines and primary thymic masses treated 
with vehicle or MRK-003 using Trizol. cDNA was synthesized using Superscript First - 
Strand Synthesis System (Invitrogen, Carlsbad, CA). To determine the effects of MRK-
003 treatment on Notch1 target genes, quantitative RT-PCR was performed using Deltex1 
and Hes1 primers as described previously59. To determine Notch1 target gene expression 
in primary tumors, quantitative PCR was performed using c-Myc, Hes1, Pre-T α, Deltex1  
primers designed using Primer Express software (Applied Biosystems, Foster City, CA). 
The primer sequences are as follows; c-Myc forward, 5'-
CTGTTTGAAGGCTGGATTTCCT-3'; c-Myc reverse, 5'-CAGCACCGACAGACGCC-
3'.  Hes1 forward 5’  - AAGACGGCCTCTGAGCACA -3’; Hes1 reverse 5’ – 
CCTTCGCCTCTTCTCCATGAT – 3’. Pre-Tα forward 5’-
CTGCTTCTGGGCGTCAGGT- 3’; Pre-Tα reverse 5’-
TGCCTTCCATCTACCAGCAGT-3’. Deltex1 forward 5’ 
TGCCTGGTGGCCATGTACT-3’; Deltex1 reverse 5’-GACACTGCAGGCTGCCATC-
3’. The copy number obtained for the gene of interest was normalized to the copy number 
for ß-Actin. 
Western Blot Analysis 
Murine leukemic cells lines were lysed in 20mM Tris buffer pH  7.4 containing 0.14 M 
NaCl, 1% NP-40, 10% glycerol, 1mM sodium orthovanadate and protease inhibitors and 
protein concentrations determined using the Bradford assay (Bio-Rad, Hercules, CA). 
Thirty five micrograms of total protein was resolved on a 10% SDS-PAGE gel, 
  
 
77 
transferred to a nitrocellulose membrane, blocked for 1h with a 50 mM Tris buffer, pH 
7.5, containing 0.15 M NaCl, 0.05% Tween 20 (TBST), and 5% (wt/vol) non fat dry 
milk, and probed overnight at 4°C with buffer containing primary antibodies. After three 
10 min washes in TBST, the filters were incubated for 1h in blocking buffer containing 
horseradish peroxidase-conjugated secondary antibodies. After three 10 min washes in 
TBST, proteins were detected by enhanced chemiluminescence (Pierce, Rockford, IL). 
The following antibodies used for immunoblotting were purchased from Cell Signaling 
Technology, Beverly, CA; phospho-p70 S6 kinase T389 (#9205), p70 S6 kinase (#9202), 
phospho-Akt S473 (#9271), Akt (#9272), phospho-S6 ribosomal S240/244 (#2215), S6 
ribosomal (#2217), phospho-4E-BP1 S65 (#9451), 4E-BP-1 (#9452), PTEN antibody 
(#9552), NotchIC Val1744 (#2421). Blots were stripped and reprobed with β-Actin 
(#A5441; Sigma, St. Louis, MO) to control for equal loading.  
In vitro Vialight Assay 
The human T-ALL cell line, TALL-1 was obtained from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) were plated at a 
concentration of 1x104 in 80µl of growth media in a flat bottom 96 well plate.  
Approximately, 10µl of MRK-003 (at concentrations ranging from 0-50µM) and 10µl of 
rapamycin (EMD Biosciences, # 553210-1mg) at either 0, 1nM, or 100nM concentrations 
were then added to each well.  On day four, new media and drug was added by spinning 
the plate and replacing 75µl per well with fresh drug and media. Plates were read seven 
days after seeding cells following the Vialight Plus (# LT07-22; Lonza Bioscience, Basel, 
Switzerland) manufacturer's protocol.  
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MTT Analysis 
In a 96 well flat bottom plate approximately 1x104 cells/ 200µL of a cell suspension was 
plated and treated for 72 hours with vehicle, 1nM rapamycin, increasing concentrations 
of MRK-003 (10-5 -101µM) or both rapamycin and MRK-003. Following treatment 20µl 
of a 5mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
solution (Sigma Aldrich, St. Louis, MO) was added and incubated for 4 hours at 37°C. 
The plate was then spun at 2000rpm for 5 minutes and the media was removed.  The 
reagent was solubilized with 100 µl of dimethyl sulfoxide (Sigma Aldrich, St. Louis, 
MO) and incubated for 10 minutes at room temperature. Plates were then analyzed at 
Α490 wavelength. Data is plotted as percent apoptosis. This value was determined by 
comparing the absorbance reading of each set of test wells to a set of control wells in 
which no drug was added and baseline proliferation was recorded. The following 
equation was used to determine effect on growth: ([absorbance of control – absorbance of 
test]/ absorbance of control) x100.  
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Figure 8. MRK-003 is a potent γ-secretase inhibitor that represses Notch1 target 
gene expression and induces apoptosis in vitro. (A) Mouse leukemic cell lines were 
treated with 1µM MRK-003 for the times periods indicated and Hes1 and Deltex1 
expression examined using RT-PCR.  Glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) was used as an internal control. (B) Three murine leukemic lines (720, 135, 
5151) were treated for 72 hours with 1µM DAPT, 1µM MRK-003, or DMSO at a final 
concentration of 0.01%.  Cells were harvested and stained with PI and DNA content 
measured by flow cytometry. (C) Thymic masses isolated directly from 
Tal1/Ink4a/Arf+/- transgenic animals were left untreated or were treated ex vivo with 
1µM DAPT, 1µM MRK-003, or DMSO for 3 days.  Cells were then stained with FITC-
Annexin V/PI and analyzed by flow cytometry. Three independent tumors were analyzed, 
one representative experiment is shown. Statistics were analyzed using a Kruskal-Wallis 
test. 
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Figure 9. GSI treatment prolongs survival in a mouse T-ALL model. (A) Effective 
compound levels in MRK-003 treated mice. Compound serum levels were analyzed 1-5 
days following continuous dosing of MRK-003 treatment.  Effective and stable 
compound levels (1 -10µM) were detected in the serum of treated mice after 12 hours at 
each drug concentration tested. (B) Plasma levels decrease during 4-day rest period. Mice 
were treated for three days with 150 mg/kg of MRK-003. Following treatment, serum 
was analyzed for compound levels. (C) Intermittent GSI dosing minimizes “on-target” 
gastrointestinal toxicity. To define a GSI dosing regimen with limited/no associated 
toxicity, mice were administered vehicle (V) or 150 mg/kg MRK-003 by oral gavage 
everyday (R1) or for three days followed by a four day rest period (R2).  Mice were 
monitored daily for loss of body weight and for evidence of diarrhea. (D) Extended 
survival in MRK-003-treated leukemic mice. Near end stage diseased Tal1/Ink4a/Arf+/- 
mice were treated with 150mg/kg of MRK-003 (n=16 mice) or 0.5% methylcellulose 
(n=14 mice) orally for three days and rested for four days until mice were deemed 
moribund. Median survival for T-ALL mice treated with vehicle is 3 days, and 18 days 
for GSI treated mice (p value < 0.005). 
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Figure 10. GSI induced gut metaplasia is reduced during the four day rest period. 
FVB mice were treated with either vehicle (0.5% methylcellulose) or MRK-003 at 
150mg/kg, once daily for three consecutive days. Intestines were harvested at indicated 
times ranging from 6 hours to 96 hours following the last dose and gut metaplasia was 
detected by PAS staining (visualized as red clusters). Scale bar, 100µM. 
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Table 1. Body weight is maintained in mice treated with successive cycles of 
intermittent GSI dosing. 
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Figure 11. GSI treatment induces apoptosis of leukemic cells in vivo. (A) Leukemic 
mice were treated with a 150mg/kg dose of MRK-003 or with vehicle for three days.  
Tumor sections were fixed in 10% buffered formalin and number of apoptotic cells 
quantified using TUNEL assay. (B) Bar graph representing the fold change in TUNEL 
positive cells compared to vehicle. Ten independent fields/section were counted to obtain 
the representative value. 
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Figure 12.  GSI-treated tumors do not appear to develop GSI resistance. Thymomas 
from MRK-003 or vehicle treated mice were harvested from the animals at sacrifice and 
converted to in vitro culture. (A) Leukemic cell lines from vehicle and GSI treated mice 
were treated for 48 hours with 1 µM MRK-003 or DMSO carrier.  Cell lysates were 
examined for intracellular Notch1 levels by immunoblotting with intracellular Notch1 
(anti-Notch1IC Val1744) and anti-β Actin antibodies. (B) Leukemic cell lines, generated 
from vehicle and GSI treated mice, were treated with vehicle or 1µM MRK-003 for 3 and 
6 days.  Cells were then assayed for DNA content by staining with propidium iodide 
followed by flow cytometry. The figure is a representative experiment using cell line 
6838. 
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Figure 13. Notch1 target genes are repressed in GSI treated leukemic 
Tal1/Ink4a/Arf+/- mice.  At sacrifice, thymomas were harvested from vehicle and MRK-
003 treated mice and c-Myc (A), Pre-T α (B), Deltex1 (C), and Hes1 (D) expression 
quantified using real time PCR.  The copy number for each gene was normalized to the 
copy number for β Actin. The following result is an average of three independent 
experiments. The mouse T-ALL cell line 720 was treated in vitro with 1µM MRK-003 or 
DMSO for 72 hours and used as a positive control in these experiments. 
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Figure 14.  mTOR activity is detected in primary murine leukemic cells. (A) 
Thymomas from untreated mice were harvested at sacrifice and tumor sections were 
fixed in 10% buffered formalin. Sections were then stained with antibodies to phospho-
S6 ribosomal protein (p-S6RP) or phospho-Akt (Ser473). Scale bars are 50µM. (B) At 
sacrifice, thymomas were made into single cell suspensions. Cells were then treated ex 
vivo with DMSO or 10nM rapamycin for time points indicated. Cells were then 
harvested, stained with an intracellular p-S6RP antibody, and analyzed by FACS. 
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Figure 15.  Notch1 positively regulates the Akt/ mTOR pathway in murine T-
ALL cell lines. (A) Reduced level of mTOR substrates are observed when murine T-
ALL cell lines are treated with GSI. Primary murine leukemic lines were treated with 
1µM MRK-003 or DMSO for 48 hours.  mTOR activity was assayed by 
immunoblotting cell lysates with anti-phospho-p70 S6 kinase or phospho-S6 
ribosomal antibodies. p70 S6 kinase and S6 ribosomal were used as loading controls 
(B) Notch1 regulates Akt activity in some mouse T-ALL lines. Akt activity was 
assayed by immunoblotting cell lysates with anti-phospho-Akt Ser 473 antibody. Akt 
was used as a loading control. Fold reductions in kinase activity were determined by 
densitometry and represent ratios (phospho/total) normalized to DMSO treated 
samples. 
A.
B.
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Figure 16. GSI and rapamycin treatment in vitro induces massive apoptosis of 
mouse T-ALL cells and cooperates to suppress mTOR activity. (A) Mouse T-ALL 
cell lines, 135, 5046, and 5151, were treated with DMSO, 1µM MRK-003, 10nM 
rapamycin, or with 1µM MRK-003 and 10nM rapamycin for 24 hours.  Cells were 
assayed for DNA content by staining with PI followed by flow cytometry. (B) mTOR 
activity is ablated when mouse T-ALL lines are treated with GSI and rapamycin. Mouse 
T-ALL lines, 720 and 5046, were treated with DMSO, 1µM MRK-003, 10nM rapamycin, 
or with 1µM MRK-003 and 10nM rapamycin and mTOR kinase activity assayed by 
immunoblotting the cell lysates with phospho-p70 S6 kinase antibody after 18 hours. 
Total p70 S6 kinase was used as a loading control. Fold reductions in kinase activity were 
determined by densitometry and represent ratios (phospho/total) normalized to DMSO 
treated samples. (C) At low pharmacologic doses, MRK-003 and rapamycin appear to 
have synergistic effects on mouse leukemic growth. Mouse T-ALL lines, 720 and 5046, 
were treated for 72 hours with 1nM rapamycin, increasing concentrations of MRK-003 
(10-5–101µM), or rapamycin and MRK-003 and growth was assayed by MTT analysis. 
The above is a representative of three independent experiments using cell line 720. 
 
  
 
91 
 
  6.22  16.5   16.9 59.5
  7.27  15.1    51.7  84.2
  11.2   28.4   51.5  93.5
 
  
 
92 
Figure 17.  GSI and rapamycin treatment inhibits human T-ALL growth and 
extends survival.  (A).  GSI and rapamycin treatment inhibits human T-ALL growth in 
vitro. Human T-ALL cell line (TALL-1) were treated with 0, 0.5, 1, 5, 10, or 50 µM of 
MRK-003 in addition to 0, 1, or 100 nM of rapamycin and ATP activity quantified using 
the Vialight Assay Kit.  (B) The combination treatment (GSI and rapamycin) inhibits 
human T-ALL growth in vivo more effectively than treatment with either agent. CD1 
nu/nu mice were injected with human T-ALL cell line, TALL-1. When tumors reached 
200mm3, xenograft mice were treated with vehicle, rapamycin, MRK-003, or a 
combination of MRK-003 and rapamycin for three weeks. MRK-003 was dosed at either 
0 or 150 mg/kg PO once a week. Rapamycin was dosed at either 0 or 20 mg/kg PO daily. 
Following treatment, tumors were callipered and body weight was recorded. Bar graph 
indicates relative tumor volumes at sacrifice. The following statistics were analyzed by a 
t-test; vehicle vs. rapamycin (p=0.0012), vehicle vs. MRK-003 (p=0.3252), rapamycin vs. 
rapamycin + MRK-003 (p=0.00192), MRK-003 vs. rapamycin + MRK-003 (p=0.0001). 
(C) GSI and rapamycin treatment inhibits human T-ALL growth in vivo and increased 
overall survival. Following three weeks of treatment with vehicle, MRK-003 
(150mg/kg/week), rapamycin (20mg/kg daily), or MRK-003 and rapamycin, T-ALL-1 
xenograft mice were monitored for tumor recurrence. Tumor free survival was compiled 
on a Kaplan-Meier survival plot. Data was analyzed by a logrank test (p=0.058). 
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CHAPTER IV 
 
 
 
 
Early Thymic Progenitors are Enriched in 
Leukemia-Initiating Potential 
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Figure Contribution: 
Kathleen Cullion performed all of the experiments presented in this chapter, excluding 
Table 3. Kathleen Cullion generated the material for the evaluation of the Notch1 
mutational status of preleukemic progenitors, however, the sequencing and mutational 
analysis was performed by Jessica Tatarek. 
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Introduction 
 Overexpression of TAL1 is found in 60% of human T-ALL patients and 
approximately 80% of these patients also co-express LMO proteins 28. Thus, TAL1 and 
LMO gene activation are common genetic events in human T-ALL. TAL1 expression is 
associated with a poor prognosis compared to other subtypes of T-ALL, with a 5-year 
survival of 43% 28. These findings highlight the need for new therapeutic strategies for 
TAL1+ T-ALL patients.   
 Leukemia-initiating cells (L-ICs) are a relatively rare population of leukemic cells 
that like normal stem cells, have the ability to both self-renew and differentiate. L-ICs 
have been suggested to be refractory to current therapy 336-338, suggesting that therapeutic 
relapse may result from a failure to eradicate the L-IC population. Therefore, the high 
rate of relapse observed in TAL1+ T-ALL patients might suggest that current therapies 
fail to eliminate the L-IC population. However, whether a majority of T-ALL patients 
harbor a L-IC population remains controversial 302,303,339.  
 To address whether murine T-ALL harbors L-ICs, we used a mouse model of T-
ALL in which the Tal1 and Lmo2 oncogenes are misexpressed during mouse thymocyte 
development by the proximal Lck promoter. We find that Tal1/Lmo2 transgenic mice 
exhibit thymocyte developmental arrest that results in significant expansion of DN3/DN4 
thymic progenitor populations. Using a Transgenic Notch Reporter mouse (TNR) to 
detect Notch active cells, we find increased Notch activity in these expanded preleukemic 
DN3/4 progenitors. These preleukemic DN3/4 progenitors are also oligoclonal and 
harbor Notch1 mutations. By analyzing Tal1/Lmo2 tumors that arise between 4-to-6 
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months, we demonstrate that DN3-like and DN4-like progenitors are maintained within 
the tumor. We find the tumor-associated DN3-like progenitors enriched in the ability to 
initiate leukemia in syngeneic mice compared to the more differentiated DP leukemic 
blasts. These studies support the idea that mouse T-ALL harbors a leukemia-initiating 
cell (L-IC) population and suggests that the L-ICs are enriched within the tumor-
associated progenitor populations.  
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Results 
DN3/4 thymic progenitor population is expanded in preleukemic Tal1/Lmo2 mice.  
  Ectopic Tal1 expression in the thymus interferes with E47/Heb function and leads 
to repression of E47/Heb-regulated genes that are critical for thymocyte development. 
Consequently, thymocyte differentiation is perturbed in Tal1 transgenic mice 58. Typically 
the differentiation arrest occurs in the DN stage of development, resulting in an 
accumulation of DN thymic progenitors. Greater than 40% of T-ALL patients coexpress 
both TAL1 and LMO1/2 oncogenes 28. Coexpression of Tal1 and Lmo1 or 2 oncogenes in 
murine thymocytes via the proximal Lck promoter accelerates leukemogenesis and 
interferes with thymocyte maturation to the DP stage (Figure 18A and 51).  
  We observed a significant reduction in the overall thymic cellularity in 4-to-6 
week old preleukemic Tal1/Lmo2 mice compared to littermate controls (Figure 18B). 
While all thymocyte subpopulations could be detected, preleukemic Tal1/Lmo2 mice had 
significant increases in the percentage of DN thymic progenitors (range 32.4% to 63%) 
compared to littermate controls (range 1.92% to 2.9%)(p<0.005), suggesting that 
thymocyte development may be arrested in the DN thymic progenitor stage. The 
differentiation block was associated with a 2-fold decrease in the percentage of double 
positive (DP) thymocytes, as well as a 3-fold decrease in CD4 single positive (SP) 
thymocytes (Figure 18A). 
  Further analysis of the DN population in the preleukemic animals revealed an 
expansion of DN3 and DN4 progenitors. Although the percentage of DN3 and DN4 cells 
was not statistically different between preleukemic and control littermates, preleukemic 
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Tal1/Lmo2 animals had a 2-fold increase in the absolute number of the DN3 and DN4 
thymic progenitors (Figure 18C p=0.05). The differentiation arrest observed in Tal1/Lmo1 
and Tal1/Lmo2 animals was greater than that described in animals that expressed Tal1 
only 58, suggesting that Lmo proteins may cooperate with Tal1 to arrest thymocyte 
development.  
 
Preleukemic Tal1/Lmo2 thymocytes exhibit aberrant Notch1 expression.  
  Spontaneous gain of function Notch1 mutations are common secondary events in 
murine T-ALL models 228-230. While it has been suggested that these gain of function 
mutations occur during the preleukemic phase 229,340, the precise nature of the target cell 
remained unclear. To monitor Notch activity during leukemogenesis, we mated our 
Tal1/Lmo2 mice with the Transgenic Notch Reporter (TNR) mouse line. The TNR mouse 
contains a transgene with four CSL-binding sites, a minimal SV40 promoter, followed by 
an enhanced green fluorescent protein (GFP) sequence 315,341. The TNR mouse has been 
shown by others to accurately reflect Notch activity during early thymocyte development, 
angiogenesis, and hair follicle formation 315,316,341,342. In the wild type thymus, we 
observed the highest percentage of Notch active cells in DN progenitors (Figure 19A). 
Within the DN population in TNR/+ mice, we detected increases in Notch active cells in 
the DN2 to DN3 stage, followed by repression of Notch signaling as cells progressed to 
DN4 (Figure 19B). Consistent with these results, a similar pattern of Notch expression is 
found when DN thymocytes are sorted and expression of Notch1 and Notch1 target genes 
are measured 114,315. We also detected Notch active cells in the DN population of 
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preleukemic Tal1/Lmo2 animals (39%-58%) (Figure 19A).  The proportion of GFP+ DN 
thymocytes in preleukemic animals was significantly greater than that observed in TNR/+ 
littermates (46.35% compared to 14.17%; p<0.05). No significant increase in Notch active 
cells was observed in the DP, CD4SP, or CD8SP populations isolated from Tal1/Lmo2 
preleukemic or control mice (Figure 19A).  
  Notch1 expression and transcriptional activity are tightly regulated during 
thymocyte development. Notch1 expression peaks at the DN3 stage and then decreases as 
thymocytes mature to the DN4 stage 114. In preleukemic Tal1/Lmo2 mice we observed a 
significant increase in the percentage of Notch-active, GFP+ DN3/4 progenitors (Figure 
19B). Although Notch1 expression and therefore activity are normally downregulated at 
the DN4 stage, we detect marked expansion of GFP+ DN4 progenitors in the mice 
predisposed to leukemia (Figure 19B).  
  The sustained Notch1 activity in preleukemic Tal1/Lmo2 thymic progenitors 
suggested that Notch1 mutations may occur at a high frequency in these mice. To test this 
possibility, the GFP+ DN3 and DN4 cells from three preleukemic Tal1/Lmo2 mice were 
examined for the presence of Notch1 mutations. Preliminary studies performed by Jess 
Tatarek in the lab have detected multiple Notch1 mutations in both the DN3 and DN4 
preleukemic populations (data summarized, Table 3). All of the mutations identified are 
found within the PEST region of Notch1 and result in insertions that introduce STOP 
codons or alter the reading frame. These types of mutations result in truncation of the 
Notch1 protein (data not shown) and can contribute to increased Notch1 protein stability. 
Although all of the mutations identified are similar in that they are predicted to result in 
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truncation of the PEST domain of Notch1, this analysis revealed the presence of a number 
of different Notch1 mutations within the DN3 and DN4 progenitor populations. These 
findings demonstrate that Notch1 is frequently mutated in preleukemic Tal1/Lmo2 DN3 
and DN4 progenitors, thereby explaining the increased Notch1 activity detected in 
preleukemic mice.  
  To further evaluate the double negative populations expanded in preleukemic 
mice, we assessed the clonality of Notch1 active DN3 and DN4 progenitors. mRNA was 
isolated from wild type thymocytes or sorted preleukemic GFP+ DN3 or DN4 cells and 
TCRβ gene expression was determined by PCR. In wild type thymocytes, we detect 
rearrangements in 15 of the 22 TCRβ families tested, confirming the polyclonality of the 
wild type thymus (Figure 19C). In each of the three Tal1/Lmo2 preleukemic mice 
examined, the DN3 and DN4 preleukemic subpopulations appear oligoclonal, consisting 
of 3-6 predominant TCRβ rearranged clones (Figure 19C and data not shown). 
Interestingly, the types of TCRβ rearrangements differed among the three mice examined, 
but were identical between the DN3 and DN4 progenitors within each mouse. This 
analysis suggests that the increases in absolute numbers of DN progenitors in preleukemic 
animals may reflect the expansion of these Notch1 active clones.  
 
Tal1/Lmo2 tumors contain thymic progenitors and this population is maintained 
upon transplant.  
  To test whether Tal1/Lmo2 tumors contained a stem cell or progenitor-like 
population, we stained Tal1/Lmo2 tumors with CD4, CD8 or with a lineage cocktail (CD4, 
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CD8, B220, GR1, Mac1) and then stained the lineage negative cells with CD44 and CD25 
antibodies. We analyzed 25 Tal1/Lmo2 tumors and found that most (24/25) were 
heterogeneous (Figure 20A, Table 4). Tumors consisted of undifferentiated DN and 
differentiated DP or SP cells that maintain expression of the Tal1 and Lmo2 transgenes. In 
22 of the tumors where the DN population was further analyzed, 16 tumors (72%) 
contained a predominant DN3-like or DN3-like and DN4-like population of cells (Figure 
20A, Table 4). Similarly a DN population has been noted in other mouse T-ALL models 
and in human T-ALL samples suggesting that this maybe a common feature of mouse and 
human T-ALL 51,302. 
  The maintenance of the DN3-like and DN4-like progenitors within mouse T-
ALL, suggests these cells may be required to initiate disease in recipient mice. To test this 
idea, we transplanted 5 different Tal1/Lmo2 tumors into syngeneic mice and monitored the 
mice for disease. All injected mice developed disease and immunophenotyping of the 
resultant tumors revealed that in all cases the thymic progenitors were maintained, 
suggesting that this progenitor population may harbor leukemia-initiating cells (Figure 
20B).  
   To determine if the immunophenotypic heterogeneity reflects functional 
differences among Tal1/Lmo2 tumor cells, we performed a series of limiting dilution 
experiments. Three Tal1/Lmo2 tumors were injected as serial dilutions into syngeneic 
mice and recipient mice were monitored for the onset of leukemia. The first tumor 
analyzed, 8129, required injection of between 5,000 and 50,000 cells to initiate disease in 
recipient mice (Table 5). We also found that injecting fewer leukemic cells from this 
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tumor resulted in an increase in disease latency, as injection of 5x106 cells resulted in 
disease in approximately 26 days, while injection of 50,000 to 5,000 cells resulted in 
disease in 41 or 53 days, respectively (Table 5). These data indicate that the L-IC 
population in this tumor is quite rare (Table 5, estimated L-IC frequency of 1:30,735). 
Consistently, this tumor was comprised of primarily DP blasts and DN3-like and DN4-like 
precursors made up 1.3% of the tumor. While an increase in disease latency was also 
observed when serial dilutions of leukemic blasts isolated from tumor 1002 were injected 
into recipient mice, this tumor appeared to harbor L-ICs at a higher frequency than tumor 
8129. When evaluating tumor 1002, injection of 500 to 5000 tumor cells was capable of 
initiating leukemia in 2/8 and 7/8 recipient mice, respectively (Table 5). Thus, in this 
tumor the L-IC frequency was much greater and estimated to be 1:2,209. Unlike tumor 
8129, this Tal1/Lmo2 tumor contained significantly more undifferentiated DN3-like and 
DN4-like precursors (56.8% compared to 1.3%)(data not shown). The third Tal1/Lmo2 
tumor analyzed, 8159, resembled 8129 and required injection of 5000 to 50,000 cells to 
initiate disease. These data suggest that in this mouse T-ALL model, not all leukemic cells 
appear capable of initiating leukemia. Moreover, the frequency of L-ICs is variable among 
tumors and may correlate with the number of tumor-associated thymic progenitors. 
 
Tumor-associated progenitors are enriched in disease initiation potential.  
  While the presence of a leukemic initiating cell (L-IC) population has been well 
documented in AML, whether ALL is driven by a rare L-IC remains controversial 
302,303,339. To determine whether tumor-associated thymic progenitors are enriched in 
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disease initiating potential, the DN3-like population from three independent Tal1/Lmo2 
tumors was sorted, along with DP blasts, and injected as serial dilutions into recipient 
mice. The purity of the DN3-like and DP tumor cells ranged between 98.4-99.4% (data 
not shown). Mice injected with unsorted tumor cells developed disease within 24-37 days, 
as expected. 19/20 mice injected with DP cells failed to develop disease, irrespective of 
the number of DP leukemic blasts injected (Figure 21A). However, 1 of 10 mice injected 
with 1x104 DP cells did develop disease.  In contrast, 8/9 mice injected with 104 DN3-like 
cells and 5/9 mice injected with 103 DN3-like cells developed leukemia within 35-60 days 
(Figure 21A). Collectively, these data suggest that the tumor-associated thymic 
progenitors are enriched in leukemia-initiating potential.  
  It is possible that the DN3-like and DN4-like cells maintained within the tumor 
are altered DP cells that are unable to express CD4 and CD8 co-receptors. The Pre-Tα 
gene encodes the surrogate TCRα protein that associates with the TCRβ chain to form the 
pre-TCR. Pre-Tα mRNA expression increases during DN development, is highest in DN3 
and DN4 progenitors and declines in DP thymocytes 343. Therefore, we compared Pre-Tα 
expression levels in the sorted tumor subpopulations from three independent tumors. In 
two of the three tumors analyzed, the DN3-like (CD4-, CD8-, CD44-, CD25+) and the 
DN4-like (CD4-, CD8-, CD44-, CD25-) tumor cells expressed higher Pre-Tα expression 
levels than the DP leukemic blasts (Figure 21B). These data support the idea that tumor-
associated DN3 and DN4 cells may more closely resemble DN3 and DN4 thymic 
progenitors than DP thymocytes.  
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  L-ICs have two unique features, the ability to self-renew and generate more L-
ICs, while retaining the capacity to differentiate into cells with limited self-renewal 
potential. These features manifest in an immunophenotypically and functionally 
heterogeneous tumor. To determine whether the sorted tumor-associated DN3 cells 
retained differentiation potential and generated DP and SP tumor cells, we examined the 
tumors harvested from recipient mice injected with purified DN3 tumor cells. The 
transplanted tumors resemble the primary tumor and contain undifferentiated DN3-like 
and DN4-like progenitor cells as well as more differentiated DP leukemic cells (Figure 
21C). Thus, the tumor-associated DN3 thymic progenitors are enriched in L-IC potential 
and retain differentiation potential. 
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Discussion 
   Here, we have studied leukemia progression in a Tal1/Lmo2 mouse T-ALL 
model. We show that expression of these two oncogenes arrests thymocyte differentiation 
at the DN3-DN4 transition and selects for accrual of additional mutations, including gain 
of function Notch1 mutations. These thymic progenitors are maintained in most 
Tal1/Lmo2 tumors and when tumor-associated, are enriched in leukemia-initiating 
potential.  
  In models of T-ALL and other hematological malignancies, differentiation arrest 
is a common feature and several studies have indicated that differentiation arrest is central 
to the development of leukemia (as reviewed in 344). In preleukemic Tal1/Lmo2 mice, the 
DN3-DN4 transition is severely perturbed due to a sequestration and repression of the 
E47/Heb heterodimer (58 and K. Draheim manuscript in preparation). E proteins enforce 
proliferation checkpoints and regulate the expression of Rag1/2 and Pre-Tα 345, genes that 
are essential for thymocyte development. T-ALL models driven by an E2A deficiency are 
also characterized by an expansion of DN3 thymic progenitors and acquisition of Notch1 
mutations 231. Thus, the differentiation arrest may select for progenitors with increased 
Notch1 activity. Consistent with this idea, we detect gain of function Notch1 mutations 
and elevated Notch activity within preleukemic Tal1/Lmo2 DN3 and DN4 progenitors. 
Aberrant Notch1 signaling has been demonstrated to stimulate thymocyte expansion and 
can promote DP thymocyte differentiation 346. Hence, aberrant activation of the Notch1 
pathway during the DN3 to DN4 transition may contribute to the preleukemic progenitor 
expansion and the L-IC activity of cells within this population.  
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  By evaluating TCRβ rearrangements, we demonstrate that increases in the 
absolute number of DN3 and DN4 progenitors preleukemically may be the result of clonal 
expansion. Although these preleukemic populations harbor identical TCRβ 
rearrangements, we find that a majority of the Notch1 mutations identified 
preleukemically are different among the DN3 and DN4 thymic subsets. The fact that many 
of the expanded clones harbor different Notch1 mutations may suggest that Notch1 
mutations are not responsible for progenitor differentiation or expansion. Alternatively, 
these data may reflect the continued pressure of preleukemic DN3 and DN4 cells to select 
for Notch1 mutations that result in increased thresholds of Notch1 signaling. Further 
evaluation of the potency of each Notch1 mutation within the preleukemic DN3 and DN4 
thymic subsets is currently ongoing in the lab.  
  The cancer stem cell model predicts that the heterogeneity observed within most 
clonal tumors reflects an organizational hierarchy, with some cells having greater self-
renewal potential and the capability to initiate tumor growth. In the Tal1/Lmo2 mouse 
model, clonal tumors appear hierarchically organized, and contain both undifferentiated 
DN3-like and DN4-like cells and more differentiated DP and SP blasts. This heterogeneity 
is also observed in infiltrated lymph nodes/organs and importantly is maintained upon 
transplant. In addition to being immunophenotyically heterogeneous, we also demonstrate 
that Tal1/Lmo2 tumor cells are functionally heterogeneous and have evidence of a L-IC 
population. Titration analyses reveal that compared to the more differentiated DP blasts, 
tumor-associated DN3 cells are enriched in leukemia-initiating potential, suggesting this 
tumor population harbors L-ICs. 
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  Although this study suggests that in this mouse T-ALL model the tumor-
associated thymic progenitors have acquired extensive proliferative capabilities and 
maintain differentiation potential, titration analysis reveal the L-IC population comprises 
only a subset of the tumor-associated DN3 cells. These data suggest that further 
purification of this population is required to better define the L-IC in this model. These 
findings also highlight the importance of evaluating the L-IC frequency in other tumor 
populations that reside within these Tal1/Lmo2 tumors, including the DN2 and DN4 
tumor-associated progenitors. Evaluation of these other populations is essential, as the 
frequency of L-ICs observed within the tumor-associated DN3 population may simply 
reflect the presence of contaminating progenitors from another tumorigenic subset.   
  Following the further purification of the L-IC population in this murine T-ALL 
model, a critical unanswered question from these studies becomes, what specific pathways 
are activated within this L-IC enriched population and contribute to L-IC activity. Our 
preleukemic studies support the notion that aberrant Notch1 activity at this developmental 
stage may confer “stem cell-like” properties on committed thymic progenitors. If aberrant 
Notch1 signaling contributes to L-IC activity, Notch pathway inhibition may reduce L-IC 
activity in this model. It is also possible that aberrant Notch1 signaling alone in committed 
thymic progenitors is not sufficient to confer “stem cell-like” properties on these cells and 
that additional mutations are required for L-IC activity. This possibility would predict that 
Notch inhibition will have little or no effect on L-IC activity, a question we are currently 
examining the effects of Notch inhibition on leukemia-initiating activity.   
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Other critical signaling pathways, including NFκB and Akt/mTOR, may be co-
opted by sustained Notch1 signaling during this thymocyte development stage and may 
contribute to the survival, extensive proliferation, and escape from the differentiation 
arrest that is required for complete leukemic transformation.  
During thymocyte development, nuclear factor-κB (NFκB) is activated following 
pre-TCR signaling to promote survival of late DN3-DN4 thymocytes 86. Aberrant NF-κB 
activation is observed in preleukemic Tal1 thymocytes, Tal1 tumors, and in human T-ALL 
cell lines 347,348. Recent studies indicate that constitutively active NOTCH1 
transcriptionally regulates NF-κB and contributes to aberrant activation of this pathway in 
T-ALL 348. Given that NF-κB may be able to substitute for pre-TCR signaling 86 and 
promotes survival of thymocytes, it is possible that Notch1-mediated NF-κB activation is 
critical to leukemia development. The Akt/mTOR pathway also provides critical pro-
survival signals to thymocytes during β selection 118. Similarly, aberrant Akt/mTOR 
activation is found in both primary T-ALL samples and T-ALL cell lines, and is in part 
Notch1 regulated 326,349. Therefore, it is possible that the NF-κB and/or the Akt/mTOR 
pathways may become activated by Notch1 and contribute to leukemic transformation. 
Both the NF-κB and Akt/mTOR pathways are aberrantly active in a number of 
malignancies and are required for the maintenance of L-ICs in AML350,351. Interestingly, 
these pathways are not active in normal HSCs, therefore pharmacologic inhibition of 
either pathway may reduce L-ICs and bulk AML cells, but have little effect on normal 
HSC maintenance. It remains to be tested whether the NF-κB or Akt pathways are active 
in T-ALL L-ICs and are required for L-IC maintenance. 
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 In addition to deregulated Notch1 signaling, mutations in other regulators of stem 
cell quiescence may contribute to L-IC activity in this model. Loss of p16(INK4A) and 
p14(ARF), and PTEN are common genetic events in human T-ALL 352. The Ink4a/Arf 
locus is epigenetically silenced in hematopoietic stem cells and when expressed, inhibits 
stem cell self-renewal 353. Deletion of these genes, or overexpression of negative 
regulators, such as Bmi1, contributes to aberrant self-renewal in leukemogenesis 354,355. 
PTEN has also been implicated in HSC and cancer stem cell self-renewal 356-361. Whether 
Pten or Ink4a/Arf loss contributes mouse L-IC activity and/or frequency remains 
unknown, but will be considered in future experiments.  
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Materials and Methods 
Mouse Studies 
A cohort of Tal1/Lmo2 transgenic mice was generated and monitored daily for the onset 
of leukemia as described previously (Draheim and Kelliher, manuscript in preparation). 
To generate the Tal/Lmo2/TNR cohort, Tal/Lmo2 mice were mated with TNR/+ mice 
(STOCK Tg(Cp-EGFP)25Gaia/J # 005854, Jackson Laboratories, Bar Harbor, ME). 
Tal1/Lmo2/TNR mice are maintained on a mixed background ((C57BL/6J x SJL/J)F2 x 
FVB/N). To control for differences in genetic background all preleukemic studies were 
performed using TNR/+ control littermates. For mouse transplantation studies, 
Tal1/Lmo2 tumor (FVB/N) cells were washed in PBS and mixed with wild type FVB/N 
thymocytes as carrier cells. Cells were injected via intraperitoneal injection into recipient 
FVB/N mice (6-8 weeks old, Jackson Lab, Bar Harbor, ME) and mice were monitored 
daily for cachexia, lethargy, and/or ruffled coat. Diseased animals were sacrificed and 
histopathological examination was performed. L-IC frequency was determined using 
Poisson distribution statistics and the L-Calc Version 1.1 software program (StemCell 
Technologies, Inc., Vancouver, Canada). 
Flow cytometry 
Thymomas isolated directly from Tal1/Lmo2 leukemic animals were made into single 
cell suspensions by mincing with glass slides. Approximately 1x106 tumor cells were 
stained with CD4-Cy5Pe and CD8-PE or with a lineage cocktail consisting of CD4-PE, 
CD8-PE, B220-PE, GR1-PE, MAC1-PE. Lineage negative cells were then stained with 
CD44-APC and CD25-Cy7Pe (BD Pharmingen, San Diego, CA). Flow cytometric 
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analysis was performed on the FACS Caliber and FACS Aria (Becton Dickinson, 
Franklin Lakes, NJ) and sorting was performed using BD FACSVantage (Becton 
Dickinson, Franklin Lakes, NJ). Data was analyzed using Flow-Jo (Tree Star Inc., 
Ashland, OR). 
RNA Analysis 
RNA was extracted from murine preleukemic thymocytes or thymomas using Trizol. 
cDNA was synthesized using Superscript First - Strand Synthesis System (Invitrogen, 
Carlsbad, CA). To determine the effects of Notch1 target gene expression on pre-
leukemic thymic subsets, cDNA was quantitated using the SYBR green kit (Qiagen, 
Valencia, CA). Specific c-Myc, Deltex1, and Pre-Tα primers were designed using Primer 
Express software (Applied Biosystems, Foster City, CA): c-Myc forward, 5'-
CTGTTTGAAGGCTGGATTTCCT-3'; c-Myc reverse, 5'-CAGCACCGACAGACGCC-
3'. Pre-Tα forward 5’-CTGCTTCTGGGCGTCAGGT- 3’; Pre-Tα reverse 5’-
TGCCTTCCATCTACCAGCAGT-3’. Deltex1 forward 5’ 
TGCCTGGTGGCCATGTACT-3’; Deltex1 reverse 5’-GACACTGCAGGCTGCCATC-
3’. The copy number obtained for gene of interest was normalized to the copy number for 
ß-Actin.  
Mutational Analysis 
To determine the Notch1 mutational status, DNA isolated from preleukemic sorted 
thymic populations or mouse T-ALL cells was amplified by PCR with, Pfu1 Taq 
(Strategene, Ceder Creek, TX) with primers specific for exon 34 of the Notch1 gene 230. 
PCR products were run on a 1.5% agarose gel, purified (QIAquick Gel Extraction Kit, 
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Qiagen, Valencia, CA), and cloned into the TOPO TA cloning vector (Invitrogen, 
Carlsbad, CA) for sequencing using the universal M13 primers. 
TCR repertoire analysis  
To determine clonality, rearrangements of the TCRβ chain were assayed by standard 
qualitative PCR analysis, using Pfu1 Taq (Strategene, Ceder Creek, TX) and primers 
specific for mouse TCR Vβ1-Vβ18 genes and constant region as described in 362. Vβ1 –
Vβ18 primers were each paired with a the following Vβ constant primer. Vβ - 5'- 
GGCTCAAACAAGGAGACCTTGGGTGG - 3'. The amplification was performed using 
a Strategene Robocycler Gradient 96 starting with a 2 minute 94°C denaturation, 
followed by 30 cycles consisting of 20 seconds at 94°C, 12 seconds at 55°C, and 30 
seconds at 68°C and a final elongation step of 10 minutes at 68°C. PCR products were 
purified on a 2% agarose gel, subcloned and confirmed by sequencing. 
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Figure 18.  Thymic progenitors are expanded in preleukemic Tal1/Lmo2 mice (A) 
Thymocytes from four-to-six week old wild type or preleukemic Tal1/Lmo2 mice were 
made into single cell suspensions. Cells were stained with CD4-Cy5Pe and CD8-PE or 
with a lineage cocktail consisting of CD4-PE, CD8-PE, B220-PE, GR1-PE, MAC1-PE. 
Lineage negative cells were then stained with CD44-APC and CD25-Cy7Pe and analyzed 
by flow cytometry. (B) Decreased thymic cellularity in preleukemic Tal1/Lmo2 mice. 
Thymocytes were counted and total thymic cellularity was determined. (C) The absolute 
number of DN3 and DN4 progenitors is increased in Tal1/Lmo2 mice. The absolute 
number in each thymic subset was determined by multiplying the percentage of each 
thymic subset by the total thymic cellularity.  
 
 
A.
B. C.
T
h
y
m
ic
 C
e
ll
u
la
r
it
y
 (
x
1
0
7
)
wt Tal1/Lmo2
0
5
10
15
20
25
30
35
40 wild typeTal1/Lmo2
0
2
4
6
8
10
12
DN1 DN2 DN3 DN4 DN1 DN2 DN3 DN4
A
b
s
o
lu
te
 N
u
m
b
e
r
 (
x
1
0
6
)
CD25
C
D
44
7.88 1.16
46.744.2
1 10
1
10
34.5 4.94
30.829.7
1 10
1
10
WT Tal1/Lmo2
9.87
2.38
1.92
83.5
0.66
2.532.4
41.7
CD8
C
D
4
1 10
1
10
1
10
102
103
104
1 10 102 103 104
102
103
104
102 103 104
102
103
104
102 103 104
102
103
104
102 103 104
 
  
 
115 
Figure 19.  Notch1-active thymic progenitors are expanded in preleukemic 
Tal1/Lmo2 mice. (A) Six-to-eight week old TNR/+ or Tal1/Lmo2/TNR mice were 
sacrificed and thymocytes stained with CD4, CD8 antibodies. DP, SP, and DN 
populations were analyzed for percent GFP+ cells by flow cytometry.  (B) Lineage 
negative cells were stained with CD25 and CD44 antibodies and GFP+ was analyzed by 
flow cytometry. The percent GFP+ cells in the DN1, DN2, DN3, and DN4 progenitor 
populations are shown. (C) Using specific primers for Vβ1-18, TCRVβ mRNA 
expression was examined in wild type and sorted GFP+ DN3 and 4 thymic progenitors 
isolated from preleukemic Tal1/Lmo2 mice.  
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Figure 20.  Immunophenotypic heterogeneity among mouse Tal1/Lmo2 tumors. (A) 
Wild type thymocytes and 25 Tal1/Lmo2 tumors were stained with CD4 and CD8 
antibodies and the lineage negative tumor cells were stained with CD25 and CD44 
antibodies and analyzed by flow cytometry. Four representative Tal1/Lmo2 tumors are 
shown. (B) Tumor-associated thymic progenitors are maintained upon transplant. 
Tal1/Lmo2 tumor cells were then injected via subcutaneous injection into recipient mice. 
At sacrifice, the immunophenotype of the transplanted tumor was reanalyzed by flow 
cytometry and compared to the primary tumor. Five tumors were analyzed, one 
representative tumor is shown. 
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Figure 21.  Early thymic progenitors are enriched in disease initiating potential. 
Tumor cells from Tal1/Lmo2 mice were stained with CD4, CD8 antibodies and lineage 
negative cells were stained with CD25 and CD44 antibodies. (A) Tal1/Lmo2 tumor cells 
were left unsorted or sorted into DN3 or DP populations by flow cytometry. Cells were 
then serially injected into recipient mice with carrier cells (wild type thymocytes) and 
mice monitored for disease. Three independent Tal1/Lmo2 tumors were analyzed. (B) 
Pre-Tα mRNA expression levels in purified into DP or DN3/DN4 tumor cells were 
quantified using real time PCR. Copy number was normalized to β Actin using the ∆∆CT 
method. Three tumors were analyzed. An average of three independent experiments on 
one Tal1/Lmo2 tumor is shown. (C) DN3 tumor cells retain differentiation potential. 
Tumors stained with CD4, CD8 antibodies and lineage negative cells were stained with 
CD25 and CD44 antibodies and analyzed by flow cytometry to compare the 
immunophenotype of tumors initiated by injection of whole tumor cells or purified DN3 
tumor cells. Three Tal1/Lmo2 tumors were re-examined, one representative tumor is 
shown.  
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CHAPTER V 
 
 
DISCUSSION 
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 Mutations affecting the Notch1 signaling pathway are common in T-ALL and it 
has been well documented that aberrant Notch1 signaling is critical for leukemic growth. 
Yet precisely how Notch1 mediates leukemogenesis remains unclear. Work addressed in 
this thesis examines the effects of Notch1 inhibition on leukemic growth in vivo, tests a 
requirement for Notch1 in leukemia initiation, and evaluates the contribution of Lef1 and 
the Akt/mTOR pathway in human and mouse T-ALL. 
 The data presented in this thesis support the idea that targeted therapies for T-
ALL could include Notch inhibition. We demonstrate that GSIs can be chronically 
administered to mice in vivo.  Using an intermittent GSI dosing schedule, we minimize 
the intestinal toxicity associated with chronic Notch inhibition and importantly extend 
survival of near end stage leukemic mice (Figure 9). Therefore, similar to effects seen in 
vitro, murine T-ALL growth remains Notch1 dependent in vivo.  
 Our analysis also reveals that mouse T-ALL is driven by a relatively rare L-IC 
population, suggesting that targeted therapies for T-ALL must be evaluated for anti-L-IC 
activity. In Tal1/Lmo2 tumors, the L-ICs appear enriched within the committed thymic 
progenitor population compared to more differentiated DP blasts (Figure 21). However, 
titration analyses reveal the L-IC population comprises only a subset of the tumor-
associated DN3 cells within a tumor. Future studies will include further purification of 
the tumor-associated DN3 population by staining with cell surface proteins commonly 
found on either hematopoietic stem cells or other L-ICs. In addition, future experiments 
will include rigorous evaluation of the frequency of L-ICs within other tumorigenic 
populations.  
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As demonstrated in other hematopoietic malignancies, the frequency of L-ICs 
may vary significantly according to the initiating and cooperating oncogenes 363. 
Therefore, in the future we will also compare L-IC frequencies among Tal1/Lmo2, 
Tal1/Ink4a/Arf, and Tal1 only mice. We will also test whether L-IC frequency correlates 
with disease latency observed among the various mouse models. Lastly, a more defined 
L-IC population would also facilitate the study of the specific genes/pathways that 
promote the extensive proliferation capacity of this population. 
 While this work was in progress, two distinct L-IC populations were identified in 
pediatric T-ALL patients. In one report, L-ICs appear enriched in the CD34+/CD4- or 
CD34+/CD7- population, suggesting a primitive HSC or multipotent progenitor drives 
human T-ALL growth 303.  In contrast, another group failed to detect CD34 expression on 
L-ICs and concluded CD34 might not be a reliable L-IC marker in T-ALL 302. This group 
does not immunophenotypically characterize the L-IC population but finds the population 
of cells with L-IC activity have the same γ and β TCR clonal rearrangements as the 
primary patient sample, indicating that L-ICs may reside within the T-cell committed 
progenitor population 302. These studies clearly indicate further analysis of the L-IC 
population(s) in T-ALL patients is required. Using the NSG model, developed during my 
thesis work (Appendix), we will examine primary pediatric T-ALL samples for L-IC 
activity. A better understanding of L-ICs in human T-ALL will allow direct comparison 
of L-IC frequencies among pediatric T-ALL samples. This model will also be useful in 
determining whether L-ICs increase upon therapeutic relapse and whether L-IC 
frequency correlates with event free survival.  
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 A recent report implicates Notch1 as a key regulator of L-IC activity in human T-
ALL 302. Our studies identify mutations that result in the truncation of the PEST domain 
of Notch1 in both preleukemic DN3 and DN4 progenitors (Table 3). We also demonstrate 
that when these progenitors are tumor-associated, they appear enriched in L-IC activity 
(Figure 21). Therefore, similar to what has been described in human T-ALL samples, it is 
possible that gain of function Notch1 mutations contribute to the L-IC activity in murine 
T-ALL. Experiments designed to test the sensitivity of preleukemic Notch1-active 
progenitors to GSI as well as the effects of GSI treatment on the L-IC activity of tumor-
associated progenitors are currently ongoing in the lab. Preliminary data suggest Notch 
inhibition may reduce the L-IC activity of tumor-associated thymic progenitors. In 2 of 3 
tumors tested, GSI treatment for 48 hours in vitro reduced the absolute number of tumor-
associated DN3-cells approximately 3.5-fold and delayed the onset of leukemia by 12 
days, on average. Whether prolonged GSI treatment will be sufficient to eradicate 
leukemia-initiating activity remains a current focus of this thesis research. 
 Our preleukemic studies reveal an expansion of Notch1 active thymic progenitors. 
C-Myc is directly regulated by Notch1 in thymocyte development and in leukemia and 
has been shown to contribute to both normal and cancer stem cell functions 59,163,238,364. 
Thus, we hypothesize that activation of the Notch1-c-Myc pathway confers limitless 
proliferation potential to thymic progenitors. Interestingly, many of the pathways 
identified in this thesis to be regulated by Notch1, all have a common connection and 
effect c-Myc expression. Lef/Tcf family members can promote c-Myc expression through 
direct transcriptional regulation 365. While the Akt/mTOR pathway can inhibit Gsk3β-
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mediated inactivation of c-Myc and also affects c-Myc translation. Therefore, it is 
possible that Notch1 acts primarily by deregulating c-Myc expression levels in T-ALL.  
 Interestingly, the preleukemic Notch active progenitors were oligoclonal, which 
could indicate that while Notch1 may drive thymic expansion, additional mutations 
including loss of Ink4a/Arf, Pten, or other mutations that potentiate c-Myc activity may 
be required for complete leukemic transformation. In the future it will be important to 
elucidate the genes/pathways specifically activated in L-ICs. To accomplish this we will 
compare the gene-expression profiling of wild type DN3 and DP thymocytes to the DN3-
like and DP leukemic cells isolated from Tal1/Lmo2 tumors.  
 Comparative analysis of gene-expression profiles and annotated pathway analysis 
between tumor maintained DN3-like and DP blasts will likely yield many potential 
targets. Therefore, our analysis will be limited to genes that show statistically significant 
differential expression and are at least two-fold over or underexpressed between the two 
groups. We will prioritize our study to include genes that are associated with self-
renewal, cell cycle, differentiation, DNA repair and to genes that regulate transcription 
and chromatin. Previous studies have identified L-IC populations to be enriched in gene 
expression signatures similar to those associated with embryonic stem cells or 
malignancies with poor prognosis 363,366. To identify potentially important genes, we will 
compare our data with these previously published data sets. Genes identified in this 
screen will be validated using quantitative PCR. We will also compare the tumor-
associated DN3 cells to normal DN3 and DP thymocytes. This gene expression analysis 
may reveal tumor maintained L-ICs resemble wild type DN3s rather than DP blasts. This 
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finding would support the suggestion that the L-IC originated within these progenitors 
and the genes that differ between the two populations may reveal candidate genes 
required for L-IC activity.  
 Data presented in this thesis also identified genes and pathways directly regulated 
by Notch1. Using a cell line in which intracellular Notch1 expression is doxycycline 
regulated, we identified Lef1 as a direct transcriptional target of Notch1 in mouse T-ALL 
cells (Figure 5). Lef1 has since been shown to contribute to leukemic expansion of 
murine T-ALL cell lines 321. However, unlike c-Myc, Lef1 expression is unable to 
completely rescue leukemic cells from the effects of Notch inhibition (Figure 6). These 
data suggest that Lef1 contributes, but is not sufficient for leukemic growth and survival. 
Interestingly, recent data suggest the role of LEF1 in human ALL might be even more 
complex. A high-resolution genome wide analysis performed on pediatric ALL samples 
detected LEF1 deletions in 1.56% of B-ALL and 8% of T-ALL cases examined 352. In a 
follow up study, highly focal deletions of LEF1 were detected in 10.6% primary T-ALL 
patient samples. This locus was then sequenced in the same 45 cases and heterozygous 
mutations were observed in an additional 6% of T-ALL patients (A. Gutierrez, personal 
communication). These data indicate that there is selection for LEF1 loss, raising the 
possibility LEF1 may function as a tumor suppressor in a subset of T-ALL patients.  
 This thesis research also demonstrates that Notch1 positively regulates the 
Akt/mTOR pathway in murine T-ALL cells (Figure 15). Although Notch1 inhibition 
reduces the phosphorylation of mTOR targets, mTOR kinase activity can be detected in 
GSI treated leukemic cells. We demonstrate that treatment with both GSI and rapamycin 
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induces massive apoptosis of leukemic cells in vitro and ablates mTOR activity.  
Moreover, we show that the administration of GSI and rapamycin significantly limits 
human T-ALL cell line growth in vivo and prolongs survival in a xenograft model (Figure 
17). Importantly, we also demonstrate that at low doses, GSIs synergize with rapamycin 
to induce apoptosis of mouse and human T-ALL cells. GSIs have been shown to 
synergize with dexamethasone and sensitize glucocorticoid-resistant T-ALL cells lines 
and primary samples to glucocorticoid-induced apoptosis 200. Collectively, these studies 
suggest that when given in combination, rapamycin, dexamethasone, and lower doses of 
GSIs may prove efficacious. These findings have urged the evaluation of GSI 
combination therapy in a phase 1 trial of relapsed T-ALL patients (T. Look and A. 
Gutierrez, personal communication). 
 The treatment of both murine and human T-ALL cell lines with rapamycin alone, 
results in G1 arrest and/or apoptosis in vitro, suggesting that the mTOR pathway is also 
critical for leukemic growth. Emerging evidence also suggests that this pathway controls 
both normal stem cell homeostasis and may also contribute to the self-renewal activities 
of leukemia- or cancer-initiating cells 356-361. In a mouse T-ALL model driven by 
conditional Pten deletion, rapamycin selectively prevented the generation or maintenance 
of L-ICs 360. These data suggest that much of the effects of the Pten deficiency on L-IC 
self-renewal may be mTOR dependent. Currently, it remains unknown whether 
rapamycin treatment alone or in combination with GSIs affects L-IC activity, a question 
we will address in future studies. 
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 While this work was in progress, members of the PI3K/AKT/mTOR pathway 
have been reported mutated or deleted in T-ALL patients. mTOR, which is regulated by 
NOTCH1 in T-ALL, is also a substrate for the E3ligase, FBXW7 180,326,349. Mutations in 
the substrate recognition domain of FBXW7 are common in T-ALL and could contribute 
to increased mTOR stability and activity. In addition, genetic mutations affecting the 
PI3K/AKT/mTOR pathway directly are found in approximately 40% of T-ALL patients. 
Gain of function mutations affecting RAS, PI3K, AKT as well as inactivating mutations in 
PTEN, SHIP1, and NF1 have also been reported (Figure 3) 367-369. PTEN also appears 
negatively regulated by NOTCH1 via HES1 in human T-ALL cell lines 327.  In PTEN 
wild type cells, GSI-mediated NOTCH1 inhibition restores PTEN signaling and reduces 
AKT activity. However, some cell lines have homozygous loss of PTEN, which renders 
cells primarily addicted to the PI3K/Akt/mTOR pathway and consequently GSI resistant. 
In murine T-ALL, no correlation between Pten loss and GSI resistance has been 
observed. In fact, in samples with Pten loss, Akt phosphorylation was reduced following 
Notch inhibition (Figure 15), suggesting that in murine T-ALL, Notch1 positively 
regulates Akt and mTOR in a Pten independent manner.  
   
Future Directions: 
 In the future we need to further define the murine and human L-ICs in our T-ALL 
models. This effort should reveal the pathways and/or genes activated in L-ICs.  This 
gene set would be predicted to contribute to leukemic self-renewal and may reveal new 
therapeutic targets. An additional priority will be to test whether L-IC frequency 
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correlates with the molecular subtype of T-ALL (TAL1, LMO, TLX1/3, NOTCH1, 
PTEN) in both murine and human samples.  
 These data support the idea that new state of the art mechanisms to specifically 
target the Notch1 pathway are essential. To date there are a number of approaches 
proposed to inhibit Notch signaling including GSIs and ADAM inhibitors that prevent 
receptor cleavage, monoclonal antibodies that interfere with receptor/ligand binding, and 
small molecules that specifically disrupt the protein-protein interactions required for 
Notch-dependent transactivation. For T-ALL, future studies should also include 
investigation of cell specific methods of Notch inhibition.  To date, a number of novel 
methods for cell specific siRNA delivery have been developed. These include 
encapsulating siRNA particles in β1,3-D-glucan to promote efficient uptake in murine 
macrophages 370 and tethering siRNA sequences to the CD7 receptor to allow for uptake 
by T-cells 371. For treatment of T-ALL, cell specific Notch pathway inhibition is likely to 
increase the therapeutic window and decrease toxicities.  
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Figure 22. A proposed model of leukemia initiation. When Tal1 and Lmo2 are 
misexpressed in DN thymocytes, E47/Heb heterodimers are disrupted and the expression 
of E47/Heb regulated genes reduced. This causes a DN3-DN4 arrest in thymocyte 
development. To overcome the arrest, DN3 progenitors may mutate the Notch1 receptor, 
which allows for progenitor expansion and possibly aberrant self-renewal capabilities. 
Most likely through additional mutations listed above, preleukemic DN3 progenitors are 
able to expand and differentiate, resulting in a heterogeneous tumor. 
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Generation of the Human T-ALL/NSG Model 
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Figure Contribution: 
Kathleen Cullion was responsible for all of the experiments presented in this chapter. 
Assistance was received for intracardiac and intraveneous injections as well as daily 
monitoring of the NSG mice from members of the Greiner Lab. 
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Introduction 
 The development of an animal model that permits engraftment of primary human 
leukemic blasts would allow for a better understanding of the molecular characteristics 
driving leukemic growth and ultimately to improved treatment strategies for the disease. 
Currently for T-ALL, experiments designed to test the effects of drug therapies are 
performed on cultured human T-ALL cell lines in vitro and in mouse xenograft systems. 
These human T-ALL cell lines were derived from relapsed patients many years ago and 
unlike primary T-ALL samples, these cell lines have frequent p53 mutations, suggesting 
that p53 function is impaired in these cell lines 372. Therefore, it is possible that drug 
responses obtained using these cultured cell lines might not accurately reflect drug 
responses of primary T-ALL samples. Therefore, we have generated a new human T-
ALL mouse model by engrafting immunodeficient NOD/scid/IL2γ-/- (NSG) mice with 
primary pediatric T-ALL cells. NSG mice have no functional T or B-cells and have a 
targeted mutation that leads to an IL-2 receptor common γ chain deficiency 373. NSG 
mice also have a complete absence of natural killer (NK) cells and more severe adaptive 
and innate immune deficiency, which results in a significant increase in the engraftment 
of human cells compared to NOD/SCID mice 373,374. Here, we demonstrate that primary 
T-ALL leukemic blasts can be engrafted in this mouse strain, allowing for the expansion 
of leukemic blasts and the identification of L-ICs. Moreover, therapeutic efficacy can be 
tested on primary leukemic samples in this preclinical model, as opposed to established 
cell lines.  
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Results 
NOD/scid/IL2γ-/- mice engrafted with human T-ALL cells develop disease 
 To test whether primary T-ALL leukemic blasts could be engrafted into 
immunodeficient mice, we transferred 5x106 blasts from human peripheral blood into 
NOD/scid/IL2γ-/- (NSG) mice. To determine optimal conditions for engraftment, 
neonates and adult NSG mice were left unirradiated or irradiated with 1 and 2 Gy, 
respectively. We then transferred leukemic blasts into either 1-2 day old NSG neonates 
by intracardiac injection or NSG adult mice by intravenous injection. Mice were 
monitored and were sacrificed upon symptom presentation (ruffled coat, weight loss, and 
hunched posture). We found the transfer of leukemic cells into NSG neonates resulted in 
a more rapid induction of disease, as NSG neonates developed disease in approximately 
49 days (Table 6, average of non-irradiated and irradiated). Adult NSG animals also 
developed disease, but required a longer latency of 78 days (Table 6, average of non-
irradiated and irradiated). Irradiation prior to the transfer of leukemic blasts did not affect 
either disease latency or level of engraftment. Therefore, the following studies were 
performed on non-irradiated NSG adult mice. 
 To evaluate the level of engraftment, cells from the bone marrow and spleens of 
diseased animals were stained with anti-human CD45 antibodies and analyzed by flow 
cytometry. Cytospin preparations of bone marrow cells were stained with Wright Giemsa 
stain. We found approximately 95% of bone marrow (Figure 23A) and 90% of the spleen 
(data not shown) consisted of human CD45 positive cells. Wright Giemsa analysis of the 
bone marrow revealed the presence of large blast-like cells with predominantly nuclear 
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staining and little cytoplasm (Figure 23A). Human CD45 positive cells infiltrated mouse 
thymus, liver, and spleen (Figure 23B). Histopathological examination of mouse tissues 
revealed organ infiltration of lymphoblasts and destruction of normal tissue architecture.  
  
Level of engraftment and immunophenotype remain unchanged following 
secondary engraftment.  
 To determine whether the properties of the disease or level of engraftment 
changed upon serial transfer, serial transplantations were performed using cells isolated 
from the bone marrow of primary recipient NSG mice engrafted with patient samples. All 
40 secondary recipients developed disease with little difference in level of disease 
engraftment observed (Figure 24, 91% vs. 99%). Similar percentages of anti-human 
CD45+ double negative (DN) and anti-human CD45+ double positive (DP) blasts were 
detected in the spleens and bone marrow of primary and secondary recipients (Figure 24), 
indicating that passage through NSG mice did not result in a change in 
immunophenotype. These data are consistent with other published findings that report no 
changes in level of engraftment, immunophenotype, or clonality following transfer into 
primary, secondary, or tertiary recipients 303.  
 
Characteristics of primary T-ALL patients engrafted into NSG mice. 
 Unsorted cells from 5 T-ALL patients were evaluated for their ability to engraft 
into NSG mice (Table 7). In 3/5 patients (05-386, 06078-061, 202-67-64), primary 
leukemic cells were successfully engrafted in recipient mice. The level of engraftment 
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was similar, ranging from 82-95% in the bone marrow (Figure 25 A-C). Of the three 
patients that have successfully serially transferred, one patient (202-67-64, Figure 25C) 
was obtained as a cryogenically frozen sample. This sample achieved similar levels of 
engraftment and similar disease latency as fresh samples, suggesting both fresh and 
frozen leukemic blasts can be engrafted into NSG recipients.  
 In patient 05-418, 4/6 NSG primary recipient mice developed disease and human 
CD45+ cells were noted in the bone marrow and spleens of recipient mice. However, 
cells harvested from primary NSG recipients did not resemble the original patient sample 
(Figure 25D). Upon arrival, 05-418 was predominantly CD4 SP (96%) and 4% of the 
tumor consisted of DN cells. No CD8SP or DP cells were detected in this leukemic 
sample. However, the cells harvested from primary NSG recipient mice have detectable 
CD4 and CD8 SP cells, raising the possibility that CD8 positive cells may reflect graft 
versus host (GVH) disease. These cells were transferred to secondary NSG recipients and 
thus far, have not resulted in disease in these mice, as of 8 months post injection. These 
data indicate that the cells isolated from the primary NSG recipient mice were most likely 
not leukemic blasts, as they did not serial transfer. Patient 05-456 was recently received 
and injected into primary NSG recipients, as of 60 days post injection, no adult recipient 
mice have developed disease as of yet.  
 
Future Experiments 
 The ability to engraft primary T-ALL blasts allows both for expansion of primary 
human leukemic cells for subsequent studies and establishes a preclinical model to test 
  
 
138 
novel treatment regimens. Preliminary evidence shows that combinations of Notch, 
mTOR, and P13K inhibitors, along with dexamethasone may have clinical efficacy in T-
ALL 326,327,349. An additional feature of this model is the ability to monitor kinetics and 
progression of human disease. Using the T-ALL NSG model, human CD45-positive 
leukemic blasts can be detected as early as 2 weeks post injection in the peripheral blood 
(Figure 26). This allows disease to be monitored overtime, which can provide a measure 
of leukemogenicity and can allow for administration of drugs to approximately the same 
amount of leukemic blasts when regimens are tested using different patient samples.  
 The development of this model will also allow for the study of L-IC activity in 
human T-ALL samples. Currently, there are only a few reports that have measured L-IC 
frequency in primary T-ALL samples and have done so using NOD/SCID mice. There is 
growing evidence that using NOD/SCID mice might underestimate L-IC frequency due 
to poor engraftment ability. The use of the more highly immunocompromised NSG 
mouse, may prove to be a more accurate measure of L-IC activity 375.  
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Materials and Methods  
Primary leukemic blasts 
Primary leukemic T-ALL samples were collected from patients treated at Dana-Farber 
Cancer Institute (Boston, MA) or at Johns Hopkins Medical Center (Baltimore, MD) and 
were obtained under signed consent in accordance with the Declaration of Helsinki and 
approval from the Institutional Review Board of the University of Massachusetts Medical 
School. Total human peripheral blood leukocytes were purified by Ficoll gradient 
separation (GE Healthcare Lifesciences, Pittsburgh, PA). Viability was assessed by 
trypan blue exclusion. 
Mice 
NOD.Cg-Prkdcscid Il2rγtm1Wjl/SzJ (abbreviated NSG, stock # 005557) were obtained from 
Jackson Laboratories (Bar Harbor, ME). Mice were housed at the University of 
Massachusetts Medical School under specific pathogen free conditions in accordance 
with Federal and Institutional IACUC guidelines. Mice are given autoclaved food and 
maintained on acidified, autoclaved water and sulphamethoxazole-trimethoprim 
medicated water (Goldline Laboratories, Ft. Lauderdale, FL) provided on alternate 
weeks.  
In vivo engraftment 
Adult recipient NSG mice were inoculated by tail vein injection with 5x106 cells in 
maximum volume of 500µl of PBS. Neonates were inoculated by intra-cardiac injections 
with 1-5x106 cells in a maximum volume of 50µl. Mice were returned to their cages and 
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examined daily for well-being. At the first signs of morbidity (weight loss, ruffled fur, 
lethargy) mice were euthanized.  
Immunohistochemistry 
At sacrifice liver, kidney, and spleen were fixed in 10% neutral buffered formalin, 
embedded in paraffin, and 5µm tissue sections were cut. Sections were stained with 
hematoxylin and eosin for histological evaluation at the DERC Transgenic Core 
Laboratory at the University of Massachusetts Medical School. Immunohistochemical 
staining was also performed using human CD45 antibodies (BD Pharmingen, San Diego, 
CA.) Images were taken using a Carl Zeiss Imager.Z1 Plan-Apochromat  (Carl Zeiss, 
Jena, Germany) with a 20X objective lens. The images were acquired using a Carl Zeiss 
AxioCam HRc camera and the imaging-acquisition software used was Carl Zeiss 
AxioVision Rel. 4.6. 
Flow cytometry 
To determine percent engraftment and to characterize the immunophenotype of patient 
samples, spleen and bone marrow were harvested from NSG mice were stained with the 
following antibodies; anti-human CD45-PerCP, anti-mouse Ly5-APC, anti-human CD4-
PE, anti-human CD8-FITC, anti-human CD20- FITC (BD Pharmingen, San Diego, CA). 
Cells were stained for 30–45 minutes, washed and fixed with 2% paraformaldehyde prior 
to analysis.  Samples were analyzed using BD FACSCalibur or FACSVantage machines 
and data analyzed using FlowJo software (Tree Star Inc., Ashland, OR).  
To monitor engraftment, mice were bled via intraocular bleeding at time points indicated 
for complete blood count (CBC) differential and for FACS analysis. Blood for CBC and 
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differential was run using the Heska CBC/Diff Veterinary Hematology System (Heska 
AG, Fribourg, Switzerland). For FACS analysis, 100µl of blood was stained as described 
above for 30-45 minutes. Cells were then washed with FACS buffer and red blood cells 
were lysed by incubating with BD FACS Lysing Solution for 5 minutes (BD Biosciences, 
San Jose, CA). Cells were then washed with FACS staining buffer and were analyzed 
using BD FACScalibur or FACSVantage machines and data analyzed using FlowJo 
software (Tree Star Inc., Ashland, OR). 
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Figure 23. NOD/scid/IL2Rγ-/- (NSG) mice engrafted with primary pediatric human 
T-ALL cells develop disease. (A) Adult NSG mice were irradiated with 2 Gy and then 
injected intravenously with 5x106 primary human T-ALL leukemic blasts. Bone marrow 
cells from diseased mice were harvested from femurs and cells were stained with anti-
human CD45 antibody and analyzed by flow cytometry. Cytospin of bone marrow cells 
harvested from a leukemic NSG mouse were stained with Wright-Giemsa. (B) Tumor 
sections of primary NSG recipient mice were stained with an anti-human CD45 antibody 
to identify human leukemic cells in the mouse thymus, liver, and spleen. Leukemic blasts 
in thymus, liver, and spleen were identified by H&E staining (panel below). 
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Figure 24. Phenotypic analysis of bone marrow from primary and secondary NSG 
recipient mice. Human T-ALL cells from patient 05-386 were injected into primary 
NSG recipients and monitored for the onset of disease. At sacrifice, bone marrow cells 
from primary recipients were injected into secondary (NSG) recipients. Bone marrow 
from primary and secondary NSG recipients was stained with CD45, CD4 and CD8 
antibodies and analyzed by flow cytometry. 
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Figure 25. Primary patient samples engrafted into NSG mice. Leukemic blasts were 
isolated from the peripheral blood/ or bone marrow biopsy from primary T-ALL patients. 
5x106 leukemic blasts were injected into NSG mice and mice were monitored for disease. 
Upon sacrifice, spleens from leukemic mice were minced and stained with anti-human 
CD45 or anti-CD4 and anti-CD8 antibodies and analyzed by flow cytometry. CD4 and 
CD8 are gated on CD45+ cells. Patient samples isolated include (A) 05-386, (B) 06-078-
061, (C) 202-67-64, and (D) 05-418. 
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Figure 26. Human CD45-positive leukemic blasts can be monitored in peripheral 
blood of recipient mice. Peripheral blood from engrafted NSG recipient mice was 
obtained by eye bleed at time points indicated. Peripheral blood was stained with anti-
human CD45 or anti-mouse Ly5 antibodies and analyzed by flow cytometry. White blood 
cells counts were monitored in engrafted NSG recipient mice at 4 and 6 weeks post-
injection.  
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